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P R E F A C E 
This "theme  plan"  is one  of  a  series of  parallel  documents  prepared 
for  Directorate-General XII  (Science, Research  and  Development)  of 
the  Commission  of  the  European  Communities,  to  support  and  inform 
the  debate  Leading  to  the  definition of  the  Framework  Programme  for 
the  Community's  Science  and  Technology  activities, 1984-1987. 
Most  of  the parallel  documents  have  been  externally  commissioned. 
For  biotechnology,  howev~r, a  substantial  amount  of  relevant  work 
in  assembling  information,  commissioning  studies, and  considering 
R&D  policy options  had  already  been  undertaken  within  the  context 
of  the  FAST  programme  in  D.G.  XII.(1) 
This  is  a  5-year  pilot programme,  established by  decision  of  the 
Council  of  Ministers  in  1978,  with  a  mandate  requiring  FAST  to  contribute 
to  the definition of  Long-term  R&D  policy  in  the  Community.  Although 
the  perspective  of  the  FAST  sub-programme  "Bio-Society"  is  Long-term, 
the  purpose  of  considering  possible developments  over  some  decades 
ahead  is still to  contribute  to  the  improvement  of  current  decisions 
and  plans.  It  seemed  therefore  wholly  appropriate  to draw  upon  the 
resources  of  FAST  in  the  current  report  ;  and  inevitably the  opinions 
and  judgements  reflect  the  author's personal  views  as developed  in  the 
context  of  FAST. 
The  views  expressed  should  in  no  way  be  seen  as  an  expression  of  the 
official policy of  the  Community. 
The  author,  while  accepting full  responsibility for  the errors, 
inaccuracies  and  opinions  expressed,  must  acknowledge  with  gratitude 
the  extensive  help  received  from  colleagues  within  DG  XII  and  other 
services  of  the  Commission.  Thanks  are  also due  to those outside  the 
Commission,  in  Member  State  administrations  and  elsewhere,  who  have 
similarly  contributed  advice  and  information. 
(1)  Forecasting  and  Assessment  in Science  and  Technology. - 4  -
S  U M M A R Y 
This  report  is  in  six  sections, progressively moving  from  presen-
tation of  basic factual  material  towards  interpretation,  judgements, 
and  consequent  recommendations. 
Chapter  I  introduces  biotechnology,  showing  why  it  is  of  major  Long-
term  strategic  significance to all  countries.  Difficulties of  defi-
nition- particularly of  the  boundary,  or  overlap,  with  other  major 
sectors  of  applied  Life  ~cience such  as  agriculture,  health  care  and 
environmental  management- Lead  to  major  problems  of  statistical  com-
parability between  countries  or  between  different  data  sources; 
but  however  approximate  some  of  the  figures  may  be,  these  uncertainties 
should  not  be  allowed  to divert  one  from  recognition  of  the essential 
unity  and  significant  development  of  biotechnology. 
Chapter  2  reinforces  this message  by  describing  the  responses  to 
biotechnology,  in  both  public  and  private  sector  R&D  activities,  by 
the  United  States and  Japan. 
Chapter  3  similarly presents  briefly the activities of  the Member 
States  of  the  European  Community,  drawing  mainly  on  published  sources 
(i.e.  not  fully  checked  with  staff  of  national  administrations  in  the 
detail  that  would  be  desirable). 
Chapter  4  describes  R&D  programmes  of  the European  Community,  current 
or planned,  in  which  biotechnology features  significantly. 
Again,  much  depends  on  definition  :  the  Community  has  several  major 
programmes  which  contain "some"  biotechnology  but  only  one  small, 
recent  programme- the Biomolecular Engineering  Programme- to which 
biotechnology  is  central. - 5 -
Chapter  5  argues  the  case  for  giving  greater  coherence  and  visibility 
to the  subject,  by  explicitly  considering  not  only  Community  R&D 
strategy,  but  "Community  Strategy for  European  Biotechnology". 
This  would  be  based  on  recognition of  the predominant  role  of  Member 
State  and  private  sector  activity,  but  would  seek  to enhance  through 
Community  action  and  policies  (including  R&D  policies)  the  effectiveness 
of  the total European  effort.  Such  effectiveness  can  be  enhanced  by  : 
1)  communication  channels  to  co-ordinate national policies  and  strategic 
choices  ; 
2)  Community  cost-sharing  R&D  programmes  such  as  those  under  way  or 
planned, plus  further  programmes  aimed  at 3)  and  4) 
3)  a~tions designed  to  reinforce  foundation  capabilities for  European 
biotechnology  :  stimulating  institutions  (education  and  research), 
networks  and  mobility  to enhance  human  resources,  and  improving 
Logistic  support  services, e.g.  including  developments  of  culture 
collections  and  data  banks  in  support  of  Life  sciences  and  techno-
Logies  ; 
4)  actions  designed  to  enhance  the operating  context  for  biotechnology 
companies  in  Europe  :  including  such  non-R&D  topics  as  agricultural 
feedstock  prices  and  the  regulatory  environments. 
Chapter  6  draws  together  the  resulting  recommendations  for  both  the 
management  of  "biotechnology  strategy"  within  the  Commission  ,  and 
the  specific  R&D  recommendations  resulting  from  the  preceding  stra-
tegic  analyses. 
The  Logic  of  chapters 4, 5  and  6  is summarised  by  the  accompanying 
diagram. / 
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BIOTECHNOLOGY 
1.  THE  SIGNIFICANCE  OF  BIOTECHNOLOGY 
Man  has  always  depended  upon  the  cycling  of  materials,  information  and 
energy  through  the  complex,  self-reproducing  systems  of  the  biosphere  ; 
even  in  a  modern  industrial  state, over  40%  of  manufacturing  output  is 
of  biological  nature  or  origin.  The  standard of  civilisation, the  very 
size of  the  sustainable population, depend  critically upon  knowledge  of 
the  applied  Life  sciences  ;  in  a  broad  sense  upon  biotechnology. 
In  these terms,  one  can  trace the  history of  biotechnology  in  man's pro-
gress  from  hunting  and  gathering,  to  herding  and  pastoral  farming,  to 
agriculture  of  ever-increasing  intensity,  culminating  in  our  own  time 
in  the  use  of  micro-organisms  in  the  controlled environment  of  fermenters 
to produce  high  value  pharmaceuticals  (penicillin), foodstuffs  or  addi-
tives  <vitamin  c, citric acid)  or  bulk  foodstuffs  (single-cell  protein)~ 
a  continuous  increase  in productivity, for  the support  of  human  popula-
tion  and  purposes.  The  need  for  mastery  of  the  life sciences  and  related 
technologies  is greater  than  ever,  as  our  population  (expanded  by  the 
past  successes  of  biotechnology- Jenner,  Pasteur, Koch)  presses  upon  or 
exceeds  the  sustainable  Limits  of  the planet. 
In  a  broad  sense,  biotechnology  is  about  the  sustainable  management  of 
systems  using  Living  elements  or  their derivatives- a  definition  which 
would  include  much  of  agriculture  and  food  production,  waste  recycling, 
health  ca~, the  production  of  chemicals, pharmaceuticals, textiles, 
organic  commodities  such  as  wood  and  rubber,  and  biomass  energy  ;  and 
extending  into  more  exotic applications  such  as  enhanced oil  recovery 
and  mineral  Leaching. - 8  -
The  European  Federation of Biotechnology, a  federation of  over  40 
learned societies founded  in 1978, has  adopted  a  narrower  definition, 
based  on  three disciplines  : 
"The  integrated  use  of  biochemistry, microbiology  and  engineering 
science  in order to achieve the technological  application  of  the 
capabilities of  micro-organisms,  cultured tissue cells, and  parts 
thereof". 
The  OECD  expert  report  (8ull, A.T., Holt, G.  and  Lilly, M.D. 
"International Trends  and  Perspectives  in Siotechnology  :  A.  State of 
the  Art  Report",  OECD,  September  1982)  has  adopted  a  broader  view  : 
"The  application of  scientific and  engineering principles  to  the  pro-
cessing  of  materials  by  biological  agents  to provide  goods  and  services  ••• 
In  our  definition  we  include  not  only the  actual process  in  which  the 
·biological  agent  is used  but  also those processes  concerned  with  its 
preparation  and  with  the processing  of  biological  materials  resulting 
from  its action". 
These  differences  of  definition  are  typical  of  an  inter-disciplinary 
field  in  rapid  evolution,  but  they give  rise to  two  specific problems 
in  this "Theme  Plan". 
- it is  impossible  to produce  reliable  internationally  comparable 
figures,  because  of  the  absence  of  standardised definition, or  of 
uniform  interpretation of  definitions  such  as  those  quoted  ; 
- much  of  the "biotechnology"  research  work  taking  place  at  both  national 
and  Community  Levels  is occurring  under  other  Labels,  rather  than  under 
research  budgets  explicitly  labelled "biotechnology"  ; 
to this problem  we  return  in  the  Later  chapters. - 9  -
There  is nonetheless  good  reason  for  using  the  single  term 
''biotechnology"  to  refer  to  what  wiLL  be  a  key  sector of  future 
industrial  development.  For  there  is a  fundamental  unity  in  the 
bases  of  the  applied  Life  sciences,  rooted  in  the  common  evolutionary 
origins  of  Living  materials, and  elucidated  by  the  biological  discove-
ries  of  recent  decades.  8ecause  of  this  common  basis, advances  in  one 
sector  are  Likely  to  have  implications  for  others  :  witness, for  example, 
the  moves  by  pharmaceutical groups, masters  of  the  new  molecular  gene-
tics, to acquire  companies  with  skills  in  the  classical genetics  of 
plant  breeding,  and  familiarity  with  the  agricultural  markets. 
~cientific Breakthroughs  which  justify the  term  "new  biotechnology" 
fundamental  discoveries  in  the  Life  sciences, particularly of  the 
role  of  DNA  as  the  molecular  carrier of  the  stored  information  in 
all genetic  material  ; 
•  techniques  for  the  manipulation, alteration, and  synthesis  of  genetic 
material  (either directly or  via  cell  fusion)  to  create  new  Life  forms  ; 
•  techniques  based  on  microbiology  for  cultivation,  screening  and  selec-
tion  of  useful  cells or  microorganisms,  and  manipulation  of  their 
behaviour  under  controlled  conditions  ; 
•  techniques  for  plant  cell  and  tissue  culture for  accelerated propa-
gation  of  useful  plants  ; 
•  downstream  processing  techniques  for  extraction,  treatment, purifi-
cation  and  conversion  of  useful  materials  following  the  biomass  pro-
duction  stBge. 
These  advances  in  biotechnology,  the  speed  with  which  they  have  occurred 
and  the  intensity  with  which  further  research  is  being  pursued,  are 
strong  reasons  for  supposing  that  they  will  Lead  to  key  sectors of 
science-based  industries  in  the  21st.  century. - 10  -
The  significance arises  also from  the  number  and  size of  the sectors 
already  being  affected  :  a  selection  are briefly described  below. 
Health  :  important  new  products  of  greater precision  and  specificity, 
such  as  monoclonal  antibodies  ;  enzyme  diagnostics  ;  the  use  of  gene-
tically engineered  bacteria to produce  by  fermentation  and  separation 
processes  hitherto unobtainable quantities of  human  proteins or  synthe-
tic analogues  ;  these  and  other products  and  processes offer  some  imme-
diate benefits for  therapy  and  research  and  the prospects  of  major  inno-
vation  in  the pharmaceutical  market  (5  76.3  bn.  world-wide). 
Food  and  feed  :  large quantities of  animal  feedstuffs  are  currently 
imported  by  Europe.  The  cereal deficit  in the Third  World  is  currently 
some  85m.  tonnes,  and  Likely  to  increase  as  world  population  grows  by 
50%  between  now  and  the  year  2000.  Biotechnology  could  be  used  to  reduce 
imports  and  to  make  Europe's  food  supplies  Less  vulnerable  in the face 
of  increasing  world  demand.  Single-cell protein for  animal  feed  is  cur-
rently  being  produced  by  a  fermentation  process  based  on  methanol  ;  other 
sources  of  fixed  carbon  (e.g.  starch,  cellulose)  could  be  similarly used, 
for  a  wide  range  of  energy  and  protein feeds  and  foodstuffs. 
Energy  :  classical  and  molecular  genetics  may  help  to produce  crops  more 
efficient  as  carbon  or  energy  sources.  In  the  Longer  term  it  may  prove 
possible to develop  biofuel  cells able  to  convert  solar to  chemical 
energy  by  splitting  water  into  hydrogen  and  oxygen. 
Other  industrial applications  :  the provision of  renewable  feedstocks 
for  the production  of  chemicals  by  fermentation  may  extend further  into 
Larger  quantities  of  Lower  value materials (it being  already  economic 
for  certain fine  chemicals  and  pharmaceuticals).  The  ability of  micro-
organisms  to  concentrate  materials  can  be  used  in  decontamination - e.g. 
sulphur  removal  ;  microbial 
11 Leaching"  is already  widely  used  in  mining 
of  metals  from  Low-grade  ores. - 11  -
Land  use  and  related policies  :  the development  of  biotechnological 
opportunities  in  the  increasingly interacting fields  of  food  processing, 
forestry,  agriculture,  chemicals,  energy  and  waste  management  will  demand 
a  reappraisal  of  the  use  of  Land.  Clearly  some  traditional  agricultural 
products  risk  being  made  superfluous,  which  will  make  it both  highly 
expensive  and  ultimately wasteful  to  continue  subsidising or  encouraging 
their  production.  On  the  other  hand  there  is  an  equally  significant 
opportunity for  attention  to  be  switched  to other products  which  biotech-
nology  can  either  make  more  feasible  in  European  conditions  or  can  convert 
into economically  or  strategically important  materials. 
At  the  same  time,  biotechnology offers  more  effective means  of  environ-
mental  control, particularly  in  the efficient treatment  or  upgrading  of 
wastes,  and  the  recycling  of  useful materials. 
It  is  clear that  biotechnology will  bring  both  threats  and  opportunities 
to  the  existing  system  of  agro-food  and  commodities  trade  between  Europe 
and  the Third  world.  Europe's  biotechnology  can  offer  know-how,  hard-
ware  and  genetic material,  which  can  improve  "bio-system management"  : 
a  term  covering  food  and  cash  crop  production  in  a  sustainable manner, 
as  well  as post  harvest  storage  and  conversion.  Biomass  energy production 
can  also  be  developed,  where  appropriate.  Europe's  biomedical  science 
also  has  much  to  contribute to  the  fight  against parasitic  infections  of 
man,  his  Livestock  and  his  crops  and  food-stores. 
In  all  the  sectors described  in the foregoing,  and  in  the  key  scientific 
disciplines  on  which  biotechnology  rests, Western  Europe  currently  holds 
a  key  position.  It  has  some  industrial  strengths  and  major,  occasionally 
outstanding,  skills  in  vaccines, antibiotics, brewing, genetics, animal 
and  plant  production.  It  has  physical, geographical  and  cultural diver-
sity giving  it  a  range  of  terrain  and  vegetation  which  is  as  wide  as  the 
reservoir  of  its  creative potential  is  deep. - 12  -
However,  one  has  only  to  study  the example  of micro-electronics to 
appreciate  how  quickly Europe  could  lose the  competitive  benefits 
currently  conferred by  its advantages. 
In  these  circumstances, governments  throughout  the  world  and  throughout 
the European  Community  are  demonstrating  their awareness  of  the  spe-
cial  importance of  this multidisciplinary activity, and  are  seeking 
the  most  effective ways  to stimulate, direct  and  support  it  :  witness 
the  series of  reports  Listed  in Table 1. 
The  Community  has  specific  responsibilities  and  capabilities which 
must  shape  its  response  to  the  challenges  and  opportunities of  bio-
technology.  It has  to perceive  and  define the nature of  these  chal-
Lenges,  and  show  where  joint action  by  the  Community  as  a  whole  is 
necessary.  Some  of  the  challenges presented by  biotechnology  are  : 
the  need  for  new  policies  and  regulations  :  e.g.  on  feedstock  prices 
(starch, glucose)  or  on  the  production of  substitutes (single-cell 
protein,  isoglucose),  with  implications for  agricultural policy  ; 
foodstuff  and  pharmaceutical  regulations  ;  patent  Law  ; 
the  avoidance  of  wasteful  duplication  of  effort  within the  Community 
e.g.  the  coordination  of  national policies on  culture  collections of 
micro-organisms  and  cells ;  data  banks  and  related  information  servi-
ces  ;  fundamental  research programmes  ; 
the  fostering  of  co-operation  between  national  industries, univer-
sities and  research  centres  ; 
•  the  creation of  a  climate encouraging  innovation. 
The  need  for  some  coordination of  strategies for  biotechnology within 
the  Community  arises  both  from  the  internal  Logic  of  efficiency within 
the  Community,  and  from  the  strong  challenges presented by  our  major 
external  competitors  ;  some  description of  which  is given  in  the follo-
wing  chapter. - 1.)  -
TABLE  1 
KEY  REPORTS  IN  BIOTECHNOLOGY 
------
~-~-~~~--~------------~-----------------------------------------------------
DATE  COUNTRY 
1974  W.  Germany 
1976  Japan 
1976  U.K. 
1977  Commission 
of  the  E.C. 
1978  Europe 
1979  France 
1979  France 
Jan  1980  w.  Germany 
Mar  1980  U.K. 
May  1980  Belgium 
Sep  1980  Canada 
Feb  1981  Canada 
Feb  1981  France 
Mar  1981  U.K. 
Apr  1981  U.S.A. 
Apr  1981  U.S.A. 
May  1981  Netherlands 
May  1981  Ireland 
Sep  1981  U.S.A. 
Sep  1981  Spain 
Oct  1981  Japan 
Nov  1981  UNIOO 
Nov  1981  Australia 
----· 
Dec  1981  U.S.S.R. 
Apr  1981  Netherlands 
~ep 1982  OECO 
..,____  __ 
REPORT 
DECHEMA,  for  BMFT  :  Biotechnologie 
MITSUI  :  Present  and  Future  of  Enzyme  Technology 
A.N.  Emery,  for  Science  Research  Countil  :  Biochemical 
Engineering 
D.G.  XII  :  Possible  Action  of  th~  E~ropean Communities  for 
the  optimal  exploitation· of  the  fundamentals  of  the  new 
biology  in  applied  research 
DECHEMA  organise first  European  Congress  of  Biotechnology, 
Interlaken,  Switzerland;  European  Federation of  Biotech-
nology  founded. 
F.  Gros,  F.  Jacob,  P.  Royer  :  Sciences  de  la  vie et  socie-
te, pour  le  President  de  La  Republique 
J.  ge  Rosnay  :  Biotechnologies et  Bio-Industrie 
BMFT  Leistungsplan  04  :  Biotechnologie 
"Spinks  report"  :  Biotechnology  :  report  of  a  joint Working 
Party  (ACARD,  ABRC,  Royal  Society) 
SPPS  :  Developpements  en  matiere  de  biotechnologies 
Miller et  al  :  Biotechnology  in  Canada 
Report  to  Minister  for  Science  and  Technology  :  Biotechno-
logy  :  a  development  plan  for  Canada 
J.C.  Pelissolo  :  La  biotechnologie, demain  ? 
Govt.  White  Paper  :  Biotechnology  (response  to Spinks) 
u.  Zaborsky  :  Biotechnology at  the  National  Science  Foun-
dation 
Office of  Technology  Assessment  :  Impacts  of  Applied  Gene-
tics  :  Micro-Organisms,  Plants,  and  Animals 
STT  :  Biotechnology  :  a  Dutch  perspective 
NBST  :  Biotechnology  Trends 
Office  of  Technology  Assessment  :  Project  Proposal  for  a 
Comparative ·Assessment  of  the  Commercial  Development  of 
Biotechnology 
La  ingenier1a genetica en  La  biotechnolog(a  <Centro  para  el 
Desarrollo Tecnologico Indus!rial, Ministerio  de  Industria 
y  Energia) 
-r-
Report  :  Heading  toward  new  Research  and  Development,  by  the 
Study  Association  for  the  Foundation of  a  long-Term  Plan  fot 
the  Development  of  Industrial  Technology 
The  Establishment  of  an  International  Centre  for  Genetic  En-
1
. 
gineering  and  Biotechnology  (ICGEB)  :  report  of  a  group  of 
1  experts  I 
Biotechnology  R&D  :  the  application of  DNA  techniques  in  re-
search  and  opportunities for  biotechnology  in  Australia 
(Commonwealth  Scientific and  Industrial Research  Organization) 
--- ---·  .... _____  !"" 
Speech  by  Academician  Ovchinnikov  at  the  Annual  General 
Meeting  of  the  Soviet  Jl.cacJ~'AY  of  Sciences 
Programmacummissie  Biotechnologie  :  Innovatieprogramma  Bio-
technologie  (Chairman  :  Prof.  R.A.  Schilpcroort) 
International  Trends  and  Perspectives  in  Biotechnology  : 
A State  of  the  Art  Report  by  A.T.  Bull,  G.  Holt  and  M.O.lilly
1 - 14  -
2.  R  &  D RESPONSES  OF  INDUSTRIAL  COMPEriTORS 
2.1.  Introduction 
The  object  of this chapter is to illustrate the basic 
strategies in this field of  competing nations outside the 
Community  (to the extent that  such policies have  been 
formulated),  their underlying strengths and trends in activity. 
However,  in appraising the relative strengths of different 
countries in this field the  question of defining biotechnology 
has to be  borne in mind.  Since different countries include 
different activities in their understanding of the term, 
objective comparisons  are difficult. 
2.2  The  United States of America 
2.2.1.  Federal  support 
The  main federal  support for activities related to bio-
technology is channelled through two  sources  :  the National 
Science Foundation  (NSF),  which is the principal federal 
agency for the support  of basic research across all fields 
of science,  and the National  Institutes of Health  (NIH), 
which are responsible for basic research in medicine  and health 
care,  and  are  also responsible for the registration of federally 
funded research work  on  recombinant  DNA.  The  U.S.  Department 
of Agriculture is also funding basic research related to 
agriculture,  some  of which  involves projects and techniques 
which  may  be  described as  biotechnology;  similarly the 
Department  of Energy's  studies of biomass-based energy sources 
involve basic biology and biotechnology. 
In fiscal year  1980,  the  NIH  supported 717  basic research 
projects  involving recombinant  DNA  at  a  cost of¢ 91.5 million; 
it is not  indicated what  further proportion of the  NIH  budget 
(¢'  3 - 4  billion) might  also be  classified as  "biotechnology". 
Zaborsky described the support  of the National  Science  Foundation 
for "biotechnology-relevant" research at  the  2nd  European 
Congress  of Biotechnology,  Eastbourne,  April  1981,  giving the 
~igures shown  in Table  2,  i.e.  ~a total of¢ 66.1  million. Program 
- Biophysics 
- Biochemistry 
- Metabolic Biol. 
- Genetic Biol. 
- Cell Biol. 
- Devel.  Biol. 
-Alt. Biol.  Sources 
- Biol.  Oceanog. 
- Applied Biol. 
- Chem./Biochem.  Pro  c. 
T  0  TAL 
Source  Zaborsky 
TABLE  2  :  U.S.  NATIONAL  SCIENCE  FOUN.DA.TION 
MAJOR  PROGRAMS  SUPPORTING  BIDrECHNOLOGY 
RESEARCH  - FISCAL  YEAR  1980 
~ 
Awards  Amount  Dollars 
(Nwnber)  in thousands 
202  1  o, 007 
222  9,087 
208  9,o81 
177  9, 276 
170  9,337 
171  8,580 
26  2,906 
101  5,841 
43  3,194 
57  2,513 
1,557  78,095 
Biotechnology Relevant 
Awards  Amount  Dollars 
(Number)  in thousands 
188  9,697 
216  9, 061 
194  8, 911 
154  8, 689 
150  8, 632 
~ 
V1 
137  7' 653 
15  2' 191 
37  2,137 
17  1' 377 
18  815 
1 '266  66,095 - 16  -
The  Office of Technology Assessment  study "Impacts of Applied 
Genetics  :  ~licro-organisms,  Plants  and Animals"  {1981)  gives 
details of federal  support for projects on  plant molecular 
genetics and other biological topics of agricultural significance. 
Their figures  include some  NSF  programmes  in plant research; 
the other main  channel is the  U.S.  Department  of Agriculture 
( US11t..).  USM. 1 s  Competitive  Grants  Program  ( 1980  :  ¢ 15  m. ) 
supports new  research directions in plant biology. 
Combining the figures mentioned suggests U.S.  federal expendi-
ture around  ~ 200  m.  p. a.  in areas relevant to biotechnology; 
the figure is sensitive to the definition used,  particularly 
with respect to the various  technologies used within the vast 
NIH  budget.  A recent  and significant example  of the latter is 
the ¢ 3.2 m.  5-year contract  awarded in June  1982  to Bolt, 
Beranek and Newman,  Inc.  for the  development  of a  nucleic 
sequence data bank  :  "upstream" from practical biotechnology, 
but  of fundamental future  importance for the life sciences. 
Of  similar importance is the software development  at  NIH 
laboratories  (Bethesda,  Maryland)  for systems  of  computer 
graphics representation of molecules  of biological interest. 
The  U.S.  Government  is examining its strategy in the field of 
biotechnology.  The  Office  of Technology Assessment  is 
responsible  and by means  of a  2  year  (1981-83)  study will 
cover the  issues of  Government  policy,  funding and regulatory 
requirements  in this field,  university/industry relationships 
and relevant features  of the educational  system,  industry 
characteristics and patent  law.  The  study will be  comparative 
and extend therefore to Japan,  West  Germany,  Great Britain, 
Canada,  France,  Switzerland and the USSR. 
2.2.2.  The  role of  industry 
It is clear that  biotechnology research and  development  is 
being substantially funded in the u.s.  As  examples  in the 
following section will suggest,  industrial funding is probably 
at least  10  times that of federal  expenditure,  which is 
concentrated at the fundamental  end of the research spectrum. 
Venture capital activity on  the other hand is aiming for payback 
in the  short  and medium  term,  particularly in the bio-medical - 17  -
and pharmaceutical fields,  whilst  larger companies  are also 
investing in longer term potential with the expectation that 
research breakthroughs during the next  ten years will lead to 
commercial  products  in the years beyond.  It is the venture 
capital activity which has  attracted the  greatest attention, 
due  to the  suddenn~s and the extent  of  support for equity 
offerings.  It has been calculated for example  that by April 
1981  well  over  100  companies  had been launched and the overall 
value  of public offerings had reached  ~ 1. 1 billion.  Two  of 
the best  known  specifically "biotechnologytt  companies  are 
Cetus  (market  capitalization¢ 400  m.  in mid  1981)  and  Genentech 
(market  capitalization ¢ 280  m.  in mid  1980).  Current  or 
recent  projects of  Cetus  (which  claims to spend ¢ 55  m.  p.a. 
on  R & D)  include high purity fructose,  a  new  veterinary 
vaccine,  and human  interferon;  work  is under way  on  other 
products  in the fields of health care,  chemicals,  food, 
agriculture  and energy.  Genentech's main  current products 
are  genetically engineered human  insulin,  human  and animal 
growth hormones,  immune  leukocyte  and fibroblast  interferons 
and veterinary vaccines.  Forthcoming products may  include 
hormones  for bone  disease treatment  and human  serum  albumin 
to replace blood loss. 
In  general the venture capital activity in the u.s.  shows 
signs of volatility and  a  significant  level  of bankruptcies 
is expected.  However,  it does  illustrate one  fundamental 
strength of the u.s.  economy,  which is the existence of entre-
preneurial scientists,  of a  market  receptive to innovative 
products  and services,  and of  a  financial  community willing 
to provide risk capital.  Examples  of the  levels of  investment 
now  taking place  and of the variety of means  used by companies 
to gain  an  involvement  in biotechnology are  : 
•  construction of an ¢  85  m.  life sciences complex  by  Dupont 
at Wilmington,  Delaware  for completion in 1983 
10  year inflation-indexed contract worth ¢ 67  m.  given by 
Hoechst  to Massachussetts  General Hospital  in order to 
undertake  molecular biology research  (and train Hoechst 
scientists) - 18 -
•  an agreement  worth ¢ 6  m.  between Dupont  and the Harvard 
Medical  School to conduct  research on molecular genetics 
. ¢ 5 m.  funding by Shell of Cetus'  work  on human  interferons, 
with a  ¢  40 m.  R & D agreement  also reported 
•  investment  of ¢  10 m.  by International Nickel,  Schering-
Plough,  Grand Metropolitan and Monsanto  in a  new  private 
company  :  Biogen  (based in Geneva;  promoters say that 
European capital was  difficult to raise) 
•  participation of ¢ 5  m.  by Dow  in Collaborative  Genetics 
•  allocation by Dupont  of 21%  of its research budget to the 
life sciences in 1982  (i.e. ¢120m.).  This proportion is 
intended to increase. 
2.2.3.  Forecasts 
The  enthusiasm of u.s.  investors has been stimulated by a 
series of forecasts  of the1ong-term market for biotechnology, 
for example,  that by T.A.  Sheets consultancy (reported in the 
Financial Times  of 25.2.82)  : 
Market  Value by Year  2000 
Alternative energy products 
New  foodstuffs 
Health care products 
(¢ billion) 
16.3 
12.6 
9.1 
Industrial chemicals made  by biotechnology 10.5 
Agricultural chemicals 
Copper  and nickel leaching 
Unspecified 
Total - 19  -
The  proliferation of  such projections reflect widely 
different  assumptions,  and definitions of biotechnology 
Source 
T.A.  Sheets 
Business  Communications 
Ci  Inc. 
Estimates of  (in ¢) 
current  1990  2000 
market 
25  m  64.8  bn 
60  m  13  bn 
n.fS~IORLD  27  bn  (us  only) 
Information Services 
(London) 
OTA  report  :  products based 
on  DNA  technology  : 
- food  and pharmaceutical 
- chemicals 
Policy research Corp.  : 
cumulative  1980 - 2000, 
products made  by genetic 
engineering techniques 
- agricultural 
- medical 
10  m  500 m 
These  estimates  seem  to reflect narrow definitions  :  the 
current pharmaceutical market  alone,  for  example,  is worth 
7.4 bn 
7.2  bn 
50/100 bn 
50/100 bn 
¢ 76.3 bn p.a.  worldwide;  the much  greater markets for food-
stuffs,  chemicals  and organic  commodities  may  all be  influenced 
by biotechnology,  and their combined scale is much  greater than 
the  above figures. 
Emphasis  of future activity :  Agriculture 
A notable feature  of activity in the u.s.  has  been the  strong 
emphasis 1  in some  widely publicised studies,  on  agricultural 
potential for the new  developments  in biology and biotechnology, 
although this has not  been matched by the patterns of  investment. 
The  Chicago  Group's report  "An  Assessment  of the  Global 
Potential of  Genetic  Engineering in the Agri-business Sector" 
points out that the market  for agricultural products is 
ncurrently close to ten ti mes  the  size of the  market  for all 
pharmaceutical health care  products  in the U.S.  alone" and - 20  -
suggests that the market  for new  agricultural products could 
outstrip the medical market  by tens of billions of dollars. 
The  report  contrasts this with the absence  of significant 
investments,  a  pattern matched also in u.s.  federal  grants 
for  genetic engineering research.  A study completed in January 
1982  by Futures  Group,  Connecticut,  "The  Impending Revolution 
in World Agriculture" similarly emphasises the new  technological 
dimension in plant  and animal  genetics. 
2.3  Japan 
2.3.1.  National Strategy 
Government  support for biotechnology dates from  the beginning 
of the '70's.  The  Science  and Technology Agency  initiated the 
new  government  biotechnology programmes  by establishing a 
Committee  for the  Promotion of Life Science  in 1973.  Rogers* 
states that  ''Since then,  the scale of Government  support for 
biotechnology R & D has steadily increased.  Support  in 1981 
for Life  Science in general is estimated at  a  minimum  of 
Yen  50,000 million(~ 195m.)  and if one  considers  only the 
more  restricted areas which  are currently referred to as bio-
technology the support  was  of the  order of Yen  5,600 million 
in 1981  (i.e.  approximately ¢ 22  million).  Government  financial 
support has  received fresh impetus  in the last year with the 
announcement  of the Ministry of  International Trade  and  Industry's 
(MIT!)  biotechnology national projects.  These  new  projects are 
the  Bio~ass Development  Project  concerned with alcohol prod-
uotion  (7  years from  1980- total budget  Yen  12,300 million  : 
¢48 m.)  and the  Next  Generation Industries national project 
which has three biotechnology themes  (10 years from  1981  - total 
budget  in the biotechnoloGY sector is in excess  of Yen  30,000 
million:  ¢116m.)." 
*  Rogers,  M.D.  ttThe  Role  of the Japanese  Government  in 
Biotechnology Research and  Development",  Chemistry and 
Industry,  7  Aug.  1982. - 21  -
MITI  is promoting its  strategy through a  ''biotechnology forumtt 
in collaboration with  14  industrial  companies,  including the 
major  chemical  groups.  Other Western reports* speak of a  10 
year biotechnology programme  offering the  industry grants  and 
subsidies worth  ~ 405  m. 
A.part  from  such action MITI  is encouraging external collaboration 
through cross-licensing contracts with advanced groups.  The 
aim  is that  such international cooperation should prevent friction 
whilst h3lping the  establishment  of international technology 
and filling gaps  in existing strength.  One  such  gap  is in the 
field of molecular genetics.  Here  there is collaboration with 
U,S.  and  European  re~8arch centres,  exemplified by an  agreement 
with the British Royal  Society,  the British Council  and the 
Science Research Council.  The  agreement  provides initially for 
exchange visits of 4  or 5  post-doctoral fellows  a  year and  may 
lead to more  ambitious plans,  perhaps  including collaborative 
research.  As  part  of  a  plan to increase Japan's attractiveness 
as  a  location for outside firms  the safety guidelines  on  genetic 
engineering have  been somewhat  relaxed.  Other steps  are  designed 
to stimulate the  competitiveness  of the  Japanese pharmaceutical 
industry through rationalisation and  improvement.  It has  been 
+ 
suggested  that the  Government  is prepared to contemplate the 
bankruptcy of up  to fourfifths  of Japan's  2,300 drug firms, 
leaving those with a  strong commitment  to research (like Takeda, 
Yamanouchi  and Shionogi).  It should be  mentioned finally that 
the Japanese  market  has until recently been effectively protected 
against foreign penetration by a  range  of non-tariff barriers, 
including the repetition of  animal tests and  clinical trials 
within Japan,  and "gentlemen's agreements"  between the drug 
firms  and the distribution network. 
2.3.2.  Industrial activitl 
Japan appears to be particularly strong in the field of 
fermentation technology and the  industrialised use  of  i~nobilised 
enzymes.  This is illustrated by Japanese  dominance  of world 
production of  amino  acids  (which may  be used as food additives 
* The  Economist,  29  Aug.  1981 
+  The  Economist,  29  Aug.  1981 - 22  -
for flavouring,  or in order to improve  the amino-acid profile 
of protein foods  or feedstuffs).  This is a¢ 1.4 billion 
market worldwide.  Ajinomoto,  one  of the major food companies, 
has  developed  (and is patenting)  genetic engineering methods 
for amino  acid production,  which it claims will double existing 
yields.  A major dairy firm,  Showa  Brand Milk Products is 
building a ¢ 20 m.  biotechnology laboratory for completion in 
~~ch 1983  and later expansion;  it started work  on  biotechnology 
research only in January 1981,  concentrating on food,  enzymes 
and fermentation.  Future plans  include pharmaceuticals.  Japanese 
firms  (Kanegafuchi,  Dianippon)  originated the development  work 
on hydrocarbon-based single-cell protein production,  although 
consumer  acceptance  problems  subsequently delayed development. 
The  technology was  subsequently licensed to European producers 
such as  Liquichima (Italy) and Roniprot  (Rumania). 
2.3.3.  Licensing and Joint  Ventures 
As  part of the strategy of establishing independent  technology 
Japanese pharmaceutical firms  are seeking to buy their way  into 
interferon production and the  genetic engineering technology 
which provides  one  route  into it.  Green  Cross has  an  agreement 
with Collaborative  Genetics for research on  a  yeast based process 
for interferon,  and another with Genex  for research on  albumin 
production.  In october  1981  it concluded an  agreement  with 
Biogen for marketing the latter's hepatitis B vaccine.  Takeda, 
Japan's largest drug company  has  signed a  contract with Roffman-
La  Roche  for  joint research and production of interferon in 
Japan,  using the  latte:t's  genetic engineering teclmology.  Other 
companies  mentioned as buying foreign  genetic engineering techno-
logy are  Kyowa  Hakko  (for interferon)  and Mitsubishi.  The  most 
significant  joint venture  involving licensing agreements  is 
Takeda's alliance with the American firm Abbott.  Takeda-Abbett 
Products have  manufacture  and marketing rights for all new 
American drug patents obtained by Takeda,  who  also have  joint 
ventures  involving Bayer  (West  Germany)  and  Roussel  Ucla.f  (France). - 23  -
Overall conclusion 
A recent  study  ( 1)  summarised Japan's strengths  and wealmesses 
in biotechnology as  follo1·1s 
Strengths  : 
a  traditional fermentation  industry 
an  established microbial fermentation business 
interchange  of University and  industrial personnel 
leadership  in South East Asia's bioscience  community 
strong financial  support 
large numbers  of trained biotechnologists 
Wealmesses  : 
rigid compartmentalisation in universities 
a  slow start in genetic engineering and separation plants 
language  and cultural isolation. 
Japan is building upon its recognised strengths  and  in a  variety 
of ways  it is aiming to  overcome  the  identified wealmesses. 
By  the  late 1980's,  having pursued the strategy of 
rationalisation and  improvement  mentioned in§ 2.3.1.,  using 
the  approach of licensing agreements,  joint ventures  and 
wholly owned  subsidiaries,  the bigger companies  will be  in a 
good  position to attack firstly the  European  and ultimately 
the American pharmaceutical  markets. 
2.4.  Other countries 
The  Soviet  Union's biotechnology is not yet  seen as  a  competitive 
threat  in fine  chemicals  or pharmaceuticals.  The  emphasis is 
rather on  the  improvement  of domestic  agriculture  and the use  of 
biomass  wastes to produce  animal feedstuffs  and thereby diminish 
external  dependence.  Current  production of single  cell protein is 
estimated by Carter* at  over  million tonnes p.a.,  with talk 
of  expandinc to  10  times this. 
(1)  Rosevear A.  :  Koshikojima- .Reflections  in a  Japanese 
Mirror - Biotech Quarterly 1,  1  March  1982. 
*  "Is biotechnology feeding the  Russians?" - G B Carter,  New 
Scientist,  23  April  1981,  216-218 - 24 
An  institution of national  and claimed international significance 
is the Institute of Plant  Industry,  which acts  as  a  centre not 
only for plant collection and diffusion but for fundamental 
research in plant  genetics. 
Canada's  Institute for Public Policy has  actively stimulated 
awareness  in that country of the potentialaf biotechnology*,  and 
a  study group was  established by the Federal Ministry for Science 
and Teclh'1.ology  in June  1980,  reporting in February 1981.  The 
resulting proposal for a  10-year,  C ¢ 483  m.  national plan ** was 
officially accepted by the  government  in April  1981. 
Principal emphasis of the plan is on  stimulating industrial and 
provincial government  investment;  and strengthening government 
research institutes,  training in multi-disciplinary biotechnology 
project work  and university and post-doctoral training.  Areas  of 
application include nitrogen fixation in the  context  of forest 
resources;  cellulose utilization and waste  treatment;  pest manage-
ment  for biomass  preservation;  plant genetics  and mineral  leaching. 
Recommendations  on  regulations for pharmaceutical patents,  new 
plant protection and registration of  DNA  experiments  seek also to 
encourage  innovation.  International collaboration is emphasized, 
and  a  national  committee  on  R & D in biotechnology is recommended, 
with strong industrial representation,  to coordinate  and evaluate 
the  implementation of the  recommendations. 
Australia's  Central Scientific and  Industrial Research Organization 
(CSIRO)  is actively recruiting staff for its Industrial Microbiology 
Unit,  to undertake research on  microbial  genetics, ~ne technology 
and industrial fermentation,  and the utilization of renewable 
raw materials  and waste  treatment.  CSIR01s  Division of Cellulose 
Research is investigating options for the utilization of all forms 
of ligno-cellulose resources  and their derivatives,  in applications 
such as 
* "Les  micro-esclaves:  vers une bio-industrie Canadienne",  Pierre 
Sormany,  Institut de  recherches politiques,  Montreal,  document 
hors  serie no.  11,  septembre  1979-
** Biotechnology:  A Development  Plan for  Canada,  report  of the working 
group  on biotechnology,  Canadian Ministry of Supplies  and Services, 
Ottawa,  February 1981. - 25  -
Constructional materials,  of enhanced mechanical properties  and 
durability; 
- paper and similar materials; 
conversion to chemicals  and fuels. 
The  Government  of  India announced in January  1982  the setting up  of  .............. 
a  National Biotechnology Board,  through which it will give  about 
UK  £  15  million for research in biotechnology over the next  3 years. 
The  expressed preference is to work  through existing research 
institutes,  and to concentrate  on  specific objectives. 
~  is actively seeking to develop  and exploit its considerable 
scientific potential  in biotechnology.  A symposium  on  nucleic 
acids  and proteins was  organized in Shanghai  in 1981,  a  cooperative 
effort between the  Chinese Academy  of Sciences  ~~d the  ~Iax-Pla~ck 
Institute.  Reported research includes  work  on  genetic engineering, 
nitrogen-fixing  6~nes,  cancer biochemistry,  and the biochemical 
basis  of folk medicine. 
The  Scandinavian countries have  strong interests  and  capabilities 
in biotechnology,  based on  strong internationally competitive 
industries in fermentation  (beer,  spirits) and in timber and 
forest  products.  Sweden  and Finland have  strong research activities 
focussed on  the exploitation of  ligno-cellulose  and the waste 
products  of the  timber  and pulp industries. 
An  interesting indication of the  geographical  spread of interest 
in biotechnology,  in Europe  and elsewhere,  is given by the analysis 
shown  in Table  3 of the participation at the  Eastbourne  Congress, 
April  1981;  ~s biassed,  of course,  by the cost  or convenience  of 
travel to the U.K. - 26  -
TABLE  3 
Analysis by country of origin of the participants in the 
Second  European  Congress  of Biotechnology 
Eastbourne,  April  1g81 
No.  of participants 
- United Kingdom  338 
- \iest  Germany  129 
- Netherlands  68 
- Switzerland  57 
- Sweden  56 
- France  !:ic:; 
././ 
- Italy  35 
- u.s.A.  34 
- Finland  29 
- Belgium  24 
- Denmark  22 
- Japan  22 
- Austria  20 
- Canada  19 
- Ireland  11 
- Spain  7 
- Yugoslavia  7 
-Hungary  6 
- Norway  6 
- Portugal  6 
- Israel  5 
5:  Argentina,  Australia, 
Bulgaria,  China,  Czechoslovakia, 
:rr:.  Germany,  Egypt,  India,  Kuwait , 
Mexico,  Poland,  South Africa  20 
TorAL  ===~!~===== 
% 
34.6 
13.2 
7.0 
5.8 
5·1 
5.6 
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3.  R &  D  RESPONSES  W.JJ·,ffiER  STATES  OF  THE  EUROPEAN  CO:MlvruNITY 
The  following sections  give fuller details of activities and  R & D 
policies relating to biotechnology,  in various member  states of the 
Community.  Although inevitably brief and uneven,  being summarised 
from  heterogenous  source materials,  these  descriptions  indicate the 
common  perceptions  and needs,  and hence  provide  a  background for the 
discussion of  European  Community  activities and policy for R & D 
in biotechnology in the following sections,  4 to 6. 
3.1.  Comparative  National  Expenditure Statistics on  R &  D 
Reference  has  been  made  to the  inter-disciplinary character of 
biotechnology and to its diverse fields  of application.  These 
make  it particularly difficult as yet to  obtain a  clear and  comparable 
quantitative picture of biotechnology R & D activity in the  member 
states of the  Community.  In particular,  the subject cuts across 
four  of the  "NABS"  categories  (Nomenclature for the  analysis  and 
comparison  of  science programmes  and Budgets)  customarily used 
in European  Community  R & D expenditure statistics: 
3.  Protection and  improvement  of human  health. 
5.  Agricultural productivity and technology. 
6.  Industrial productivity and  technology. 
10.  General  promotion of knowledge. 
However,  in order to  give  a  context  against which to appraise the 
figures  quoted below,  Tables  4  and  5  indicate,  in national  currencies 
and  ECU,  the  level  of national expenditure  on  these  NABS  chapters 
for the years  1979- 1981.  Of  the  23.2 billion units of account  (bua) 
budgeted for all areas  of civilian R & D for  1981,  the Federal 
Republ.:_c  of  Germany  accounted for 7. 1 bua,  France  6.1  bua,  United 
Kingdom  6.0 bua,  Italy 1.7  bua,  Netherlands  1.1  bua and Belgium 0.5. 
The  1980  total 1·ras  19.7  bua.  A more  detailed analysis  of the  1980 
figures  is available,  and Table  6  sho~1s  expenditure by country on 
12  areas more  closely related to biotechnology;  the  expenditure 
on  biosciences is most  likely to be  correlated with strength in 
at  least the  foundation disciplines  of  biotechnology,  but there 
are  problems  of comparability caused by the  mapping of different 
national systems  into the  1~BS categories.  The  U.K.  figuxes  appear PUBLIC  R&D  FUNDING  OF  SELECTED  NABS  CHAPTERS,  1979-1981 
N A B S  C H A P T E R S 
G)  0  0 
PROTECTION  AND  AGRICULTURAL  INDUSTRIAL 
IMPROVEMENT  OF  PRODUCTIVITY  PRODUCTIVITY 
HUMAN  HEALTH  AND  TECHNOLOGY  AND  TECHNOLOGY 
IN  NATIONAL  CURRENCIES, 
IN  CURRENT  PRICES  179  '80  '81  '79  '80  '81  '79  180  '81 
OM 
F.R.  GERMANY  m.  986  1031  1082  305  318  348  1443  1701  1825 
FF 
FRANCE  m.  1459  1719  2223  1047  1214  1573  2710  2902  3758 
LIT 
ITALY  b'.  71,0  86,1  115,3  50,1  64,3  70,4  96,9  270,0  234,2 
FL 
NETHERLANDS  m.  206  143  198  218  262  264  154  194  264 
FB 
BELGIUM  m.  2381  3356  3480  1039  1007  993  2960  3147  3164 
1: 
UNITED  KINGDOM  m.  57,2  61,0  71,1  88,3  102,5  131,7  82,4  154,5  249,4 
i 
It: 
IRELAND  m.  2,6  4,3  5,6  11,9  10,6  15,0  3,9  2,5  5,4 
: 
DKR 
DENMARK  m.  205  229  223  147  149  188  244  230  325 
EUA 
EUR  9  m.  961  1062  1211  625  712  863  1421  1834  2213 
i 
EUA 
EUR.  COMM.  m.  38,0  30,2  39,3  2,9  2,4  4,2  26,3  25,1  33,2  I 
-
EUR.  9  +  EUA  I 
EUR.  COMM.  m.  999  1101  1251  628  715  867  1448  1859  2247  ~ 
! 
Source  Statistical Office of  the European  Communities, 
CREST  I  1235  I  81 
(National  currencies) 
) 
~-· 
TOTAL 
GENERAL  ALL 
PROMOTION  NABS 
OF  KNOWLEDGE  CHAPTERS 
'79  '80  181  '79  '80 
6792  7344  7821  15838  17046 
6246  6917  8242  26477  31100 
370  553  887  1051  1550 
1615  1732  1762  2884  3106 
5612  6700  7002  18834  21099 
449  507  703  2026  2477 
11,1  15,4  18,4  ~8,0  41,2 
643  664  710  1  t..84  1698 
5031  6301  7376  16.  716  19417 
:o,3  o,s  0  2H,7  2843 
5632  6302  7376  16954  19701 
'81 
17930 
36555 
2129 
3301 
21652 
3226 
56,4 
1988 
22869 
346,4 
23215 
G>6>+®+@> 
AS  % Of  TOTAL 
'79  '80 
181 
60,1  61,0  61,8 
43,3  41,0  43,2 
55,9  62,7  61,4 
76,0  76,7  75,4 
64,1  67,3  67,6 
33,4  33,3  35,8 
77,6  79,6  78,7 
73,~  74,9  72,7 
51,~  51,0  51,0 
28,~  23,6  22,1 
51,~  50,6  50,6 
N 
00 
I IAt:ILE:  !>  PUBLIC  R&D  FUNDING  OF  .lELECTE.D  NABS  CHAPTERS,  1979-1981 
< 
N A 8  S  C H A P  T E R S 
G)  0  G) 
PROTECTION  AND  AGRICULTURAL  INDUSTRIAL  . 
IMPROVH1ENT  OF  PRODUCTIVITY  PRODUCTIVITY 
HU~IAN  HEALTH  AND  TECHNOLOGY  AND  TECHNOLOGY 
IN  M  ••  EUROPEAN  UNITS 
OF  ACCOUNT  179 
180  '81  '79  '80  • 81  '79  '80  '81  '79 
F.R.  GERMANY  ~~  393  409  427  121  126  137  575  674  719  6308 
FRANCE  250  293  371  180  207  263  465  494  628  1071 
ITALY  62,3  70,8  91,0  44,0  54,0  55,6  85,1  226,9  184,9  325 
NETHERLANDS  75,1  65,8  70,4  79,S  96,9  93,8  56,1  70,1  93,9  588 
,..., 
BELGIUM  e 
'-J  59,3  82,7  83,7  2s,g  24,8  23,9  73,7  77,5  76,1  142 
J. 
UNITED  KINGDOM  88,5  102  132  137  171  244  128  258  463  695 
:;:; 
IRELAND  3,9  6,o  8,1  17,8  15,7  21,6  5,8  3,7  7,8  16,5 
~ 
DENMARK  28,5  29,2  27,9  20,4  19,0  23,5  33,8  29,4  40,7  89,2 
EUR  9  961  1062  1211  625  712  863  1421  1834  2213  f)631 
EUR.  COMM.  38,0  39,2  ~,9  2,4  4,2  26,3  29,1  33,2  0,5  0,5 
EUR.  9  + 
EUR.  COMM.  'II 
999  1101  1251  62C.  715  867  1448  1853  2247  632 
Source  Statistical Office of  the European  Communitie~, 
CREST  I  1235  I  81 
<M.  EUA) 
> 
.®  ___ 
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I 
1 
'80  181 
179 
l 
2909  3083  6303 
1179  1317  :4542 
i 
I 
I 
I 
465  700  i 923  I 
I 
628  627  !1049 
I 
! 
165  168 
i 
469 
I 
l 
848  1305  i3135 
I 
I 
22,8  26,41  56,8 
I 
I 
84,8  88,8 I 
I 
237 
I 
6301  I 
7376  16716 
0  0,5  2377 
i 
I 
6302  17376  116954 
TOTAL 
All 
NABS 
CHAPTERS 
'80  '81 
6753  7070 
5299  6109 
1303  1681 
1125  1174 
520  521 
4139  5985 
61 ,c  81,1 
217  249 
19417  D2251 
2245  3464 
19701  23215 
Q>CD+@+@> 
AS  X OF  TOTAL 
'79  '80  I 81 
60,1  61,0  61,8 
43,3  41,0  43,2 
55,9  -62,7  61,4 
76,0  76,7  75,4 
64,1  67,3  67,6 
33,4  33,3  35,8 
77,6  79,6  78,7 
73,6  74,9  72,7 
51,7  S"1,0  51,0 
28,5  23,6  22,1 
51,4  50,6  50,6 
N 
"'  I Within 
NABS 
chapter 
(!)  protection 
& improvement 
of  human 
health 
~:  Agricultural 
productivity 
& technology 
@: Industrial 
productivity 
& technology 
@: general 
Promotion  of 
Knowledge 
SECTION 
31  :  Medical  research 
(incl.  biomedical  & engineering) 
32  :  Food  hygiene  & nutrition 
33  :  Pollution 
50  :  Research  of  general  nature 
51  :  Domestic  med.  animal 
products 
52  :  Crops  ( incl.  forestry>  + wine 
53  :  Fisching  and  fishery products 
632  :  Pharmaceutical  products 
681  :  Food,  drink &  tobacco 
686  :  Utilisation of  industrial 
agricultural &  domestic  wastes 
1013  :  Biosciences 
103  :  Research  in  medical  Sciences 
Source 
PUBLIC  R&D  FUNDING  OF  SELECTED  NABS  SECTIONS  1980  <  •ooo  EuR> 
FED.  REP ••  I  UNITED 
GERMANY  FRANCE  ITALY  NETHERLANDS  BELGIUM  IRELAND  EUR  9  *  KINGDOM 
96,513  217,074  34,876  7,958  31,435  50,766  712  439,335 
17,664  17,550  2,670  - 4,482  7,193  1,879  51,437 
133,651  58,273  12,399  32,680  14,901  35,479  365  287,750 
50,280  25,217  9,391  7,779  3,905  28,986  808  126,367 
5,961  64,918  8,176  10,363  9,578  60,688  8,586  168,270 
60,525  97,973  34,527  35,633  10,074  60,855  3,652  303,260 
9,067  18,743  1,950  2,364  1,200  13,594  2,627  49,546 
- - 11,435  - 1,736  - - 13,170 
16,875  24,877  4,997  - 3,766  2,508  222  53,245 
- - 1,560  - 1,563  979  12  4,114 
126,811  196,798  30,934  - 26,005  3,6-19  1,092  385,258 
632,238  121,657  68,076  - - 98,025  71  920,067 
Statistical Office of  the European  Communities, 
CREST  I  1235  I  81  * no  comparable  Danish  figures - 31  -
to under-represent the country's degree  of activity as  compared 
with France  and  Germany.  The  total under biosciences,  385.3 mua, 
may  perhaps  be  set against  the fi.gure  quoted by Rogers for Japanese 
government  expenditure for life sciences in general  :  50  bn Yen, 
i.e.  195  rnua  :  it is probable that this is of  the right  order in 
indicating by how  much  the  spending of the  European  Community 
countries  in total exceeds that  of the Japanese. 
Adding together chapters  31  (Medical  research =  439.3  mua)  and 
103  (Medical  Sciences= 920.1)  gives  a  figure for the  EC  approaching 
1i bn  eua;  approximately half the budget  of the u.s.  National 
Institutes of Health. 
A general  omission from the  public sector R & D statistics is the 
public provision of staff and facilities in the university or 
polytechnic institutions of the higher education sector.  Although 
generally provided under the Ministry of Education budgets,  the 
extent  and  quality of  these  are  of  primary  importance for R & D 
capabilities.  A Commission  sponsored report  on  the training 
facilities for biotechnology in various  countries  of  Western  Europe 
has  been  assembled by the Education Working  Group  of the  European 
Federation of Biotechnology. - 32  -
3.  2.  Federal Republic of  Germany 
Germany  has for many  years  had outstanding industrial strength in 
all major areas  of biotechnology.  Initiatives by  DECEm:.~ (Deutsche 
Gesellschaft fUr  Chemisch$Apparatewesen)  led to a  major report 
in 1974  on  the significance of biotechnology,  and a  revised version 
was  subsequently commissioned by the Bundes  Ministerium fur Forschung 
und Technologie  (BMFT)*. 
BivlFT  has  summarised in "Leistungsplan 04"  a  clear picture of 
federal  expenditure  on  R & D in biotechnology  :  Figure  1  is based 
on the plan as  at January  1980,  showing the  breakdown  of the 
planned expenditure  of  DM  53  n1.  on  project expenditures.  To  this 
should be  added some  DM  17  m.  for support  of the institutions listed. 
More  recently armounced plans  speak of  increasing expenditure 
from the  current  D::  55  m.  to  DM  70  m.  p. a.  (from  22  to  28  mua). 
The  major single public  commitment  to biotechnology is the 
Gesellschaft fur Biotechnologische Forschung  (GBF),  at Braunschweig-
Stockheim,  where  a  wide  range  of research is undertaken;  ranging 
from  g~netic manipulation to fermenter  operation and the exploration, 
with pilot-scale plant,  of downstream processing operations.  1982 
total budget  DH  31 • 6  m.,  of which  DM  5.  4 for  investment  in expanded 
facilities. 
The  Bl.'IFr  also makes  extensive use  of collaborative  agreements  in 
research with many  other countries,  including Japan,  Sweden,  and 
Canada  as well  as with EC  partners. 
The  major strengths of  German  biotechnology lie in its large 
chemical  and pharmaceutical  companies  :  Hoechst,  Bayer,  Boehringer 
Mannheim  and Boehringer  Ingelheirn.  There  is close collaboration 
with educational institutions,  and with the industrially-orientated 
activities of the  GBF  and  DEC~:~ (the  chemical  equipment  manufact-
urers'  association).  Full-time degree  courses  in biotechnology are 
* Biotechnologie  :  Studie uber Forschung und  Entwicklung : 
Moglichkeiten,  Au.fgaben  und Schwerpnnkte  der Forderung, 
DECHEI~1A,  1 97 6. PROJECT 
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provided only at the  Institute for Fermentation and Biotechnology 
in Berlin;  but  many  universities  and technical high schools include 
courses supplementary to basic courses  in microbiology and bio-
chemistry.  There  are links also with the Technical High School, 
Zurich. 
Hoechst  is the largest of the chemical/pharmaceutical companies, 
and attracted considerable  comment  vthen  in 1981  it signed a  1 0-year 
¢ 67  m.  research agreement  with Massachusetts  General Hospital for 
work  on  molecular biology and eenetics.  This  should be  seen in the 
context of the  co~pany's total pharmaceuticals R & D budget  of some 
¢ 270 m.  p.a.  With  B1~ support,  Hoechst  has  developed a  single-
cell protein now  being tested for human  nutrition (production scale 
2000 t.p.a.). M~o 
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growth  of  expenditure  on  biotechnology  R&D  in  FRG,  1974  - 1982. 
Project  expenditures 
Institutional  support  : 
Gesellschaft  fur  Biotechnologische  Forschung 
Gesellschaft  fur  Strahlen  und  Umweltforschung 
Kernforschungsanlage,  Julich - 36  -
3.3.  France 
The  President  of the republic commissioned from Professors 
Gros,  Jacob  and  Royer  a  major study,  "Sciences  de  la Vie  et 
Societe",  whose  publication in October 1979  is a  convenient 
starting point for the consideration of public policy towards 
biotechnology.*  This report  was  very "European",  emphasizing that 
the diversity and complexity of advanced teaching and biological 
research have  become  such that  a  sufficiently large  and competent 
group  can be  organized only on  a  european rather than a  national 
basis.  Concerning the basic tools of biological research -
measuring devices,  biological materials,  buildings,  databanks 
and stocks of living materials,  France is seen as  excessively 
dependent  on foreign sources;  but with adequate  investment,  the 
authors believe that French industry should be  able to correct the 
situation within  10 years. 
Food production is seen as  an essential issue - perhaps by the 
end  'Jf  the century,  as  great  a  problem as  energy;  a  strategic 
challenc;e  of particular significance to a  country lvith France's 
vast agricultural potential.  French industry is seen as  strong 
in foods  (though other sources see it as  fragmented in comparison 
1·1ith  major U.S.  or  even U.K.  firms),  as  comfortably placed in 
pharmaceuticals,  but  as weak  in biological  and medical technology. 
The  research proposals  made  by  Gros,  Jacob  and  Royer  include: 
Fixation of  nitrog~n - interdisciplinary collaboration involving 
botanists,  biochemists,  geneticists and  agronomists. 
Bioconversion of cellulosic resources  and  wastes  - including 
an  inventory of cellulose resources. 
Fuel  alcohol  programme  - based on  existing fermentation alcohol 
capability,  cellulose wastes  and skill in  yeast  biochemistry. 
* An  English summary  of the  Gros,  Jacob  and  Royer  report,  the 
de  Rosnay  report  and the  Pelissolo report,  together with cownents, 
has  been  made  by  K.  Sargeant.  Available from  FAST,  DG  XII, 
Commission  of the  European  Communities. - 37  -
Mass  culture of animal  and plant  cells,  for biological derivatives, 
pharmaceutical  products,  monoclonal  antibodies;  importance  of cell 
banks  and  gene  banks  is again emphasized. 
Biological  equipment  and reactor engineering  a  major development 
effort needed to produce  modern,  well-instrumented equipment. 
Parallel to the  Gros,  Jacob  and  Royer  report,  Joel de  Rosnay 
produced an  informative document*  giving details of  French  and 
foreign capabilities in each area of biotechnology. 
A briefer and  more  succinct,  policy-oriented report  was  requested 
by the  Prime  J,~inister,  2.:1d  J .-C.  Pelissolo was  charged with this 
responsibility.  His  report**  considers  in turn public sector 
research,  industry and the controlling administrations.  It aims 
to identify strengths  and weaknesses,  and  identify the principal 
problems  to be  solved to ensure  industrial success. 
Public sector research  is~en as  of  good  quality,  but  its transfer 
to,  and exploitation by,  industry is restricted by inflexibilities. 
Pelissolo sees  French  industry as  backward in biotechnology,  behind 
not  only the U.S.  and  Japan,  but  also  Germany,  the  Netherlands  and 
Britain.  There  is insufficient knowledgein the  leading industrial 
teams.  He  considers  several specific fields  in detail  : 
Health  :  strong in pharmaceuticals  (Rhone-Poulenc,  Roussel Uclaf), 
but  a  1najor  deficit  in antibiotics;  strong in immunology. 
- Agriculture  :  risks  of external  dominance  of the  seed industry; 
need to exploit  INRA  genetics  research and  in vitro plant  propagation 
know-how. 
* "Biotechnologies et Bio-industrie",  Joel  de  Rosnay,  Documentation 
Franc;aise,  1979. 
** "La Biotechnologie,  Demain?",  Jean-Claude  Pelissolo,  rapport 
aM.  le Premier Ministre,  Documentation  Franc;aise,  December  1980 - 38 
- Agro-food  :  traditional brewing and  cheese-making lacks research 
and innovative strength;  more  active are the food- and feed-
additive industries,  with 10-So%  (depending on  product)  of world 
amino  acid production  (70-80% exported),  and a  major converter of 
maize  (1.3  m.  tonnes  of maize  processed into  300 different products). 
The  EEC  iso-glucose regulations are seen as  damaging,  benefitting 
only the Japanese  and still more  the American producers  in the  long 
term. 
Chemicals  :  biotechnological applications currently modest,  but 
expected to increase  :  French industrial interest  lagging behind 
American and  German  activity. 
Pelissolo sets as first objective the increase  of France's research 
potential,  and  of its utilization by industry.  High quality funda-
mental  research must  continue to be  financed by the state.  France 
must  mruce  good  from foreign  sources  what  she  cannot find at home, 
buying foreign firms,  and promoting academic  and industrial exchanges 
of research fellows with the best foreign laboratories.  Amongst 
his many  specific recommendations,  Pelissolo includes the creation 
of  an international mission for biotechnology,  to orchestrate and 
stimulate national  competence  in the field. 
The  subsequent  change  of  administration in France  has  reinforced 
the strong public  commitment  to biotechnological development, 
coordination now  being focussed by the creation of  the new  "Mission 
Biotechnologie",  under Professor Pierre  Douzou. 
This  has  a  budget  of  some  FF  70  m.  (10  mua)  to spend on  research, 
but  as  its Director has  pointed out,  funds  from  other national 
agencies  (such as  the Agence  Nationale  de  Valorisation de  Recherches) 
could double  or treble this  amount.  The  research Ministry's new 
strategy involves the creation of four  technology transfer centres 
for biotechnology  :  Compiegne,  Toulouse  and  two  in Paris  :  Institut 
Pasteur and  an  expanded  INRA  fermentation centre.  At  these scientists 
will be  encouraged to work  in collaborative "cells" with engineers 
and technologists  from  local companies.  Also  planned are some 
60-80 fellowships  to encourage scientists in universities  a.nd  in. 
industry to do  applied research and/or update their knowledge. - 39  -
Altogether it is estimated that the  French Government  will  spend 
some  FF  200  m.  (29  rnua)  on  education and research in biotechnology 
in 1982.  Strategic planning of  industrial biotechnology is centering 
particularly on  the  capabilities of Rh8ne-Paulenc  and  Elf~quitaine. 
A study by SEDES*,  for the Ministry of Industry's  Delegation for 
Innovation and Technology,  illustrates the  emphasis placed on  the 
potential role of small  and  medium-sized enterprises in biotechnology. 
This  emphasis  tends to be  linked with the  exploitation of agricultural 
products,  by products  and wastes. 
3 • 4 •  l..!.ili 
The  Italian government's  support  for  Life  sciences  and  biotechnology 
research  is  channelled  mainly  through  the  Council  for  National  Re-
search  (CNR).  The  CNR  has  announced  a  Task  Programme  on  Genetic  Engi-
neering,  to  run  1983-1987,  with  a  financial  commitment  of  the  order  of 
15  m.  ecu  over  the 5  years  (i.e.  same  3  m.  p.a.). 
There  has  also  been  reported  (scrip,  26  July  1982)  a  plan to  spend 
Z 91  M.  on  biotechnology  over  the  next  5  years,  over  half  of  this  from 
government  and  the  rest  from  private  industry.  The  intention  is to 
draw  extensively  upon  the  experience gained  in  CNR's  biomedical  techno-
Logy  research  programme  (say  10  m.  p.a.  ;  10  +  3  = 13  m.  ecus p.a.) 
0  her  public  sector  initiatives  include  support  for  biomass  energy 
projects, and  generous  financial  support  for  the  installation of 
anaerobic  digesters  to  cope  with  the  effluent  problems  of  intensive 
animal  units. 
Of  special  interest  is  the  recent  agreement  between  FIAT  (Soria),  ENI 
(Sclavo)  and  MONTEDISON  (Carlo Erbe  - Fasmitalia)  for  common  precompeti-
tive  research  in  the  field  of  monoclonal  antibodies  for  diagnostic 
methods  and  developments.  Financing  of  this project  (1983-1986)  has 
been  approved  by  the  government  amounting  to 5  m.  ecu,  through  an 
IMI  contract  (via Tecnobiomedica). 
*  "Les Bio-Industries  •••  des  Opportunites  pour les P.MI", 
Ministere  de  L'Industrie,  Programme  National  d'Innovation,  no  5· * 
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CNR  also  supports  research  centres  in universities  such  as the Insti-
tutes of  Genetic  Biochemistry at  Pavia  and  Naples.  There  are  several 
other  strong  centres  in  the  life sciences  (Milan,  Genoa,  ~ari ••• ) 
and  others  in agricultural  research. 
Turning  to  industrial  research, mention  should  be  made  of  the  advanced 
work  in  immobilised  enzymes  for detoxification, particularly within 
*  FIAT  (Soria)  and  ENI  (SNAM  progetti). 
Italy**has developed a  substantial fermentation  industry for 
pharmaceuticals,  citric acid and  single cell protein. 
Pharmaceutical producers  include the following companies 
Ankerfarm  {Milan)  :  Glaxo  subsidiary 
synthetic penicillin 
tetracyclines  and  semi-
Archifar  (Milan)  :  owned  by l'IIontedison  and  EliT 
semi-synthetic penicillin 
erythromycin and 
Ciba-Geigy  (Fervel)  (Naples) 
Cynamid  (US)  :  tetracyclines 
steroids,  eifamycin,  cephalosporins 
Farmitalia  :  (Montedison)  (Milan)  :  semi-synthetic penicillins under 
license from Beechams 
cephalosporins  C 
tetracyclines,  doxorubicin,  alkaloids, 
Icar  (ESF)  (Milan)  :  semi-synthetic penicillins and cephalosporin 
Istituto Biochemica Italiano  (Milan)  :  penicillins and cephalosporin 
Lepetit  (Milan)  :  Dow  subsidiary :  sifamucin,  anti-tuberculosis 
antibiotic,  tetracyclines 
Peirrel  (Milan  and  Capra)  erythromycJne .  and tetracyclines 
A~SORENI, the  research  association of  the  ENI  group,  have  recently 
conducted,  with partial Community  support,  a  wide-ranging  review  : 
"Blood  detoxification  :Problems  and  Perspectives", published  (1982) 
by  Frances  Pinter,  London. 
~* This  section draws  inter alia upon  information provided in 
J.  de  Rosnay' s  ttBiotechnologies  et Bio-industrie",  Documentation 
Frangaise,  1979. - 41  -
Squibb  (US)  (Kilan)  :  penicillin  G 
Proter  (Milan)  :  tetracyclines,  cephalosporins 
Lark  (Milan)  (Montedison subsidiary)  :  cephalosporin. 
de  Rosnay  comments  that  the  rapid growth of pharmaceutical  production 
over the last  30  years was  attributable to the  absence  of patent 
protection for these products,  a  situation which  has  given rise 
to international friction in the  past. 
In the  other fields  of fermentation,  single-cell protein from  hydro-
carbons  was  previously seen as  of major  importance. 
AJ.\fiC  of Milan,  the  petrochemical branch of  :E:N"I,  was  in partnership 
vli th BP  for the production of single-cell protein  (SCP)  in Italy. 
A factory based on  n-alkanes  as  feedstock,  using yeasts to convert 
this into protein,  was  constructed in Sardinia,  with a  capacity of 
100,000 tonnes p.a.  Restrictions  on  the sale of  SCP  caused the 
termination of the project,  without  the plant being commissioued.  The 
experience  of Liquichemica,  who  licensed the Japanese process  from 
Kanegafuchi  was  similar;  delays  in clearance for the  marketing of 
the product  forced the  group  into liquidation. 
3.5.  The  Netherlands 
An  extensive  review of both biotechnology and  of Dutch national 
capability was  published in April  1981*  by STT,  and some  key points 
from this are  swrunarized belm-1.  A.  government-sponsored cormni ttee 
was  set up  in May  1981,  under the  chairmanship of Professor 
Schilperoort  of the University of Leiden,  with the  aim  of coordinating 
research on  the Netherlands  and increasing its emphasis  on  commercial 
applications.  The  committee  includes experts from  industry, 
universities,  and the  governmental  applied research organization TUO. 
Four million florins  a  year has  been made  available for the bio-
technology committee  to allocate to selected projects. 
* nBiotcclmology  :  a  DutGh  perspective",  ed.  J.H.F.  van Apeldoorn; 
Stichting Toekomstbeeld der Techniek  (Netherlands  Study Centre 
for Technology Trends) - 42-
The  committee  reported in April  1982,  and has  emphasized not the 
creation of new  centres for biotechnology,  but the strengthening of 
cooperation between government  institutes,  universities and industry. 
It urges the  government  to provide extra support to stimulate  innovation 
in biotechnology - at least an extra 75  m.  florins  (28  mua)  over the 
period 1982-1988  - drawing on  the  government's fund for industrial 
irmovation,  and  in addition to a  separate  (and much  larger) planned 
budget  for biotechnology.  (Other reports speak of a  ~ 1  billion 
5-year plan for  government  expenditure  to encourage  R &  D by industry 
into biotechnology and micro-electronics.) 
The  co~~ittee emphasizes  applied research in areas  of existing 
strengths of Dutch  companies  - agriculture,  dairy industries, 
fermentation  and antibiotics;  and for future  research,  the develop-
ment  of host-vector systems,  somatic cell hybridisation,  second 
generation enzyme  reactors,  and downstream processing technology. 
The  committee,  echoing widespread earlier calls from  industry, 
universities,  and the  STT  report,  reco1;~mends bringing the  Dutch 
regulations  on  D~  experiments  into  line with the  less strict criteria 
adopted elsewhere,  and harmonized on  a  single national,  rather than 
municipal,  basis.  The  construction of  a  laboratory for work  at· P3 
containment  level at  TNO  has been delayed pending advice from  the 
Committee  on  the  E~hical Implications  of  Genetic Engineering. 
Professor Schilperoort sees the need to  improve  internal communication 
structures  :  Dutch industry and universities often have  extensive 
contacts  abroad at the  expense  of national collaboration.  The 
country has  a  large fermentation  industry,  in many  respects  of 
in·~ernational standard.  Research facilities  ou~side industry are 
very limited,  reducing the potential for  international competitiveness. 
In the food  industry,  Dutch breweries  and dairy plants are sophis-
ticated and  internationally competitive. 
The  Netherlands  has  an excellent tradition of microbiology,  bioche~­
istry and  process engineering,  and  has  a  leading international position 
in effluent treatment,  developed in response to the needs  of the 
food industries. - 43  -
The  company  Gist-Brocades  is burope 1s  major producer of penicillin, 
tvi th corresponding expertise  in  fermentation  technology.  It is 
also  one  of the world's  major producers  of  enzymes,  and  is carrying 
out  intensive study on  their proQuction,  isolation and application, 
on  laboratory and commercial  scale.  Related research is under way 
at the universities of Delft  and  vlageningen;  details of these 
and other university research centres are  given in the  STT  report. 
Gist-Brocades  has  acquired other enzyme  producers  such as  Wallerstein 
(in the U.S.A.)  and  Rapidase  (in France). 
Akzo  has  also a  range  of  phar~aceuticals based on  fermentation 
technology.  Its subsidiary,  Organon,  produces steroids  (including 
contraceptives),  and  has been  one  of the first  companies  to market 
a  product  based on  monoclonal  a~tibodies (a pregnancy test).  Another 
subsidiary,  Glucono,  is one  of Luropes principal producers  of 
gluconic acid. 
The  Netherlands has  a  major sugar industry,  Centra~l Suiker,  and 
its subsidiary Chemie  Combinatie  produces  lactic acid by fermentation 
of sucrose  • 
.). 6.  Denmark 
Biotechnology  is critical for  Denmark.  The  agricultural  <24%),  food 
(34%)  and  chemical  (10%)  industries  together dominate  the "manufacturing" 
economy.  Everyone  has  heard  of  the  Carlsberg  brewery,  with  its tradi-
tional  skills  in  brewing,  which  have  supported  the  creation of  an  inter-
national  research  centre  with  outstanding  competence  in plant  genetics 
and  cell biology.  Everyone  has  also  heard  of  Novo,  which  dominates  the 
world  market  in  industrial  enzymes.  Novo  practised  biotechnology before 
the  word  was  invented,  and  is  now  arguably  the world's  Leading  company  in 
the  field. 
Denmark  spends  about  700  m.  Kron,er  annually  <86  m.  e.u.a., private and 
public  sector)  on  biotechnology  research,  somewhat  Less  than  1%  of 
product  value,  but  heavily  biased  towards  the  chemical  sector  (Novo 
contributes  200  m.  of  this).  It is now  being  argued  by  some  that  re-
search  investment  in  agriculture  and  food  should  be  increased. ~ 44  -
In  1978  the  Danish Technical  Research  Council,  under  the  chairmanship 
of  Prof.  O.B.  Jorgensen,  took  the first  initiative in the field  and 
supported projects  in genetic  engineering  scale-up  problems  (with parti-
cular  reference to genetic stability), product  recovery  (with  spe-
cial  reference to selective  recovery  of  intracellular products)  and 
on  protein  synthesis.  More  recently a  Ministry  of  Industry "initiative 
group"  recommended  against  creating  a  new  institute specially for 
biotechnology  because  the  subject  was  of  such  widespread  interest that 
it needed  to be  practised widely. 
In  April  1981  another  Ministry of  Industry ''initiative group"  was  formed 
under  the  chairmanship  of  Prof.  Ulrik  V.  Lassen,  research  manager  of 
Novo,  to  consider  applied genetic  engineering  in  Denmark.  It  reported 
in  November  1981  and  recommended  that  individual  research proposals 
should  be  supported  and  that  appropriate guidelines or  rules  to govern 
applied  research  and  industrial  use  of  genetically manipulated  micro-
organisms  should  be  developed.  Its principal  recommendation  was  that 
a  Working  Group  to study  the genetic  manipulation of  microorganisms 
should  be  set  up  at  the Technical University,  with  a  view  to the appoint-
ment  of  a  Professor  at  a  later date.  This  working  Group  was  started 
in October  1982  and  now  comprises  4  scientists and  3  technicians.  It 
will  aim  to  provide  a  microbial  genetics  service to  industry. 
Denmark  is developing  a  unique  biotechnology,  based  on  a  unique  biotech-
nology  company,  with  cooperation from  government  and  university. 
3.7.  The  United Kingdom 
3.7.1.  Government  policy and  Research  Council  activity 
A major report  on  biotechnology was  published in April  1980  by a 
Joint  Working  Party drawn  from  the  Cabinet's Advisory  Council for 
Applied Research and  Development,  the Advisory Board for the 
Research  Council  and the Royal  Society.  This  report  is usually 
lmo\m  as  the  Spinks  Report  after the  Chairman  of the  \iorking 
Party Sir Alfred Spinks,  formerly Director of research at  ICI. - 45-
Seeine larc;e potential  gro1.vth  in the field,  both for existing 
industries  and  nev1  ones,  the report recommended  a  policy of 
"technology push" reflected in a  firm  commitment  to strategic 
applied research,  and funded by Government  intervention.  Detailed 
reco~nendations were  that Research Councils  should spend at 
least £  3  m.  (5  mua)  annually on  biotechnology research,  and 
that the  Government  should spend about  i  2.5  m.  a  year  (including 
existing projects)  in a  coherent  progr~~e of industrial R & D 
to involve  industry,  Government  research establishments,  universi-
ties  and research associations.  A further specific recommendation 
was  for the  establishment  of a  research-oriented biotechnology 
co~pany (suggested cost£ 2m.). 
The  initial response  of the  Government,  in a  ~fuite Paper  on  the 
subject,  v;as  strongly to emphasise  the role of  market  forces 
and  the private sector,  to exploit British scientific and 
technical discovery and build up its competitive position by 
importing good  developments  through  licences  or otherwise  as 
well  as  from  its own  research and development. 
Initally at least this attitude,  and the  lack of specific policy 
on  the vital area of education for biotechnelogy,  were  seen as 
clearly differentiating the  Government's  attitude from that  of 
France'  vlest  Germany  and Japan. 
Subsequently however,  many  aspects  of the  Spinks  report  have  been 
implenented,  illustrated by the following developments  : 
~ the Research Councils now  spend  ~ore than £  7  m.  between them 
on  narrowly defined biotechnology,  and  a  coordinating committee 
has  been set up;  indeed their evidence  to the  Parliamentary 
Committee  currently investigating biotechnology gave  the figures 
shown  in Table l,  suggesting a  possible total exceeding £  25  m. 
(4.3  mua),  mainly attributable to the  medical  "underpinning" 
research. - 46  -
TABLE  7  U.K.  Research Councils  annual  expenditure on biotechnology  (£m) 
-Agricultural Research Council  (total 1982/83  budget  about  £92  m.  p.a.)= 
genetic manipulation  (primarily of plants) 
•  other areas of biotechnology including 
veterinary,  vaccines  and monoolonal  antibodies etc 
for veterinary diagnostics  2.5 
related "under-pinning" research  "of the same  order" 
total  "about  £5  m." 
-Medical Research  Council  (total budget  about  £107m.  p.a.) 
•  on  a  rigorous definition (research directed 
specifically to the  development  of something with 
a  foreseeable  commercial  end such as  a  vaccine 
or diagnostic reagent)  =  of the order of 
•  conceptual underpinning = molecular biology, 
molecular  genetics = ttapproximately  1  on  (verbal 
answer);  underpinning research  (e.g.  in the 
chemistry,  organisation and function  of  genes) 
= "the  Council  spent  £17  million in 1980-81" 
(written submission) 
total 
Science  and &1gineering Research Council 
•  current  annual  expenditure an biotechnology 
research  (divided roughly into two-thirds for basic 
biological research and one-third for engineering 
research)  =  £1  million;  including  DNA,  aspects  of 
:nicrobiology and  molecular  genetics,  irrunobilised 
enzyme  and cell systems,  fermentation  including 
downstream processing,  \vaste  treatment  and the 
leaching of metals  from  ores.  Planned to  increase 
to £2.5  million by  1985/86 
total 
- Natural Environment  Research  Co1mcil 
present  role relatively minor  (£0.6 million p.a.), 
but  many  interactions  and areas  of research activity of 
relevance  : 
management  of biomass  production  (seaweed,  organic 
wastes,  woodlands,  algae,  fish) 
•  selection,  sterile culture and propagation of 
tree clones  total 
18.7 
0.6 - 47  -
•  pest  control 
•  ecology,  physiology,  biochemis-try  and  genetics  of 
micro-organisms  (soil and  aquatic) 
•  taxonomy,  culture technology and  collections 
For the 4 councils  25.3 
Bource:  ~inutes of Evidence  of the House  of  Commons  Education,  Science 
and Arts  Con:ni ttee,  Session 1981-82,  "Biotechnology"  :  21  April  and 
10 May  1982. 
- a  special Biotechnology Directorate  has  been established within the 
Science  and  Engineering Research Council to coordinate  SERC  grants for 
research in the field and  encourage British scientists to take up 
research in related areas. 
- a  coordinating committee  between  Government  departments  h8s  been 
set up. 
- Department  of  Industry support for R & D is now  at  least at the  level 
recommended  in the  Spinks report  (£2.5  m.)  and  support for industrial 
investment  in the area is around £15  rn.,  a  further i:  16  m.  industrial 
support  programme  was  announced  in  December  1982. 
- the University Grants  Committee  has  been given  increased funds  of 
£1  m.  per annum  to finance  20  extra teaching posts  and research  (a 
________  _. 
recent  report  estimated that over the next  10 years,  Britain would  require 
1000 extra graduates  and  4000 technicians trained in biotechnology); 
- a  research-oriented company,  Celltech,  has  been  launched,  its £12  m. 
capital being 44%  public  (via the Brit  ish Technology  Group),  56%  private 
(~udential Assurance,  Midland Bank,  British COl:.monwealth  Shipping, 
Technical  Development  Capital).  Celltech  has  a  special  responsibility for 
commercialising  useful  discoveries  from  Medical  Research  Council  supported 
Laboratories;  plans  are  also  well-advanced for  the  Launch  of  a  correspon-
ding  company  to exploit  the  results of  work  financed  by  the Agricultural 
Research  Council. - 48  -
Whilst  the  United Kingdom's  academic  strength  in  the  field of 
biotechnology  rests on  the  large number  of  University departments  in 
the  life sciences,  many  associated with  research units dependent  on 
the  Research  Councils,  its commercial  strength is based  on  large and 
successful  companies  in  chemicals,  pharmaceuticals  and  food  processing, 
whose  research  and  production facilities,  like those of  some  important 
subsidiaries of  non  UK  firms  <e.g.  G.D.  Searle), are based  in the 
UK.  Imperial  Chemical  Industries Ltd.  has  played  a  major  role  in the 
development  of  biotechnology  in Britain,  in  fields  as diverse as  plant 
protection  chemicals  (esp.  pyrethroids)  sewage  treatment  (e.g.  the 
deepshaft  process  for  recycling,  on  limited  land  space,  water  contami-
nated  by  organic  effluents)  and  single cell protein.  The  last  has  been 
widely  publicised,  with  the  bringing on  stream early in  1981  of  the 
"Pruteen"  plant  producing  60.000  tons of  single cell protein  rich  in 
the essential amino  acid  lysine.  Based  on  a  feedstock  of  methanol, 
produced  from  North  Sea  gas,  this  product  competes  with  soya  and  other 
protein  sources.  It  has  also had  to overcome  the  regulatory hurdles 
faced  by  any  novel  feedstuff.  The  project  itself is of  great  signifi-
cance  as  a  prototype  for  large-scale biotechnology and  the development 
of  the  related process  engineering.  Attempts  to  improve  the energy 
efficiency of  the micro-organism  have  included  the  use  of  genetic 
engineering to produce  a  manipulated variant.  Others  strong  in  the field 
of  biotechnology  include  innovative pharmaceutical  firms  such  as  Glaxo 
and  Beechams.  Groups  such  as  ICI,  Shell  and  BP  have  significant  research 
and  production  capabilities  in  pharmaceuticals  and  agricultural  chemicals. 
Major  food  firms  and  brewing  groups~in the  UK  are also showing  active 
interest  in  biotechnology,  eg.  Rank  Hovis  McDougalls  fungal  single cell 
protein  and  Grand  Metropolitan  Hotels  investment  in  Biogen  (the only 
European  shareholder). 
Unilever's expertise at  all stages of  vegetable oil production  (palm 
tree cloning)  and  manipulation  (inter-esterification, e.g.  to  convert 
palm-oil  mid-fraction to the  equivalent  of  cocoa  butter fat)  is another 
strong  point  of  Anglo-Dutch  biotechnology  :  the  examples  cited  indicate 
also the  Third  World  implications. ---------------------------------------------
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Belgium  has  a  strong  chemical  industry,  and  outstanding  strengths  in 
its universities  and  research  institutes  in  the  biomedical  sector  (e.g. 
the  Institute for  Cellular and  Molecular  Pathology)  and  in  plant genetics 
(University of  Ghent),  as  well  as  in other areas  <e.g.  bacteriology  in 
various  institutions).  The  international  pharmaceutical  companies  are 
also attracted by  the  high  quality environment  provided  by  the  research 
teams  in  the various universities of  the  country.  The  rather open  economy 
and  the  presence  of  numerous  multinational  companies  (chemicals,  pharma-
ceuticals,  foods)  create the  problem  for  the  public  authorities of 
balancing the  advantages  of  attracting foreign  investment  against  the 
drawbacks  of  a  potential  internal  "braindrain"  into  these  companies, 
with  insufficient  spin-off benefits to the  local  economy. 
At  the  level  of  the  regional  authorities,  Wallonie,  Flanders  and  Brussels 
are  seeking to attract  foreign  investment  in  high  technology  sectors  such 
as  biotechnology.  At  the  level  of  the national authorities,  the  IRSIA  -
a  national  industrial  research association - is coordinating  R & D 
projects on  biotechnology topics  <e.g.  on  vectors, yeasts,  plant  tissue 
culture)  at  Belgian  research  centres,  and  funded  by  14  Belgian  companies 
(2  year  budget,  some  BF  200m). 
The  SPPS  (National  Science  Policy  Department)  is supporting  centres 
of  excellence  in  molecular  biology,  through  "Concerted  Research  Actions" 
in  the  last  10  years  (yearly budget  200  MFB). 
In  addition,  the organization of  a  coordinated collection of  micro-
organisms  has  been  started,  with  fungi  at  Louvain-La-Neuve,  and  bacteria 
at  Ghent. 
3.9.  Ireland  -------
Ireland,  like Belgium,  is vigorously  seeking  to attract foreign 
investment,  to take advantage  from  its developed  educational  system, 
and  to  stimulate greater exploitation of  the  country's under-utilised 
agricultural  potential. - so  -
fhe  1981  report  by  the National  Branch  for  Science  and  Technology, 
"Biotechnology Trends",  emphasised  chemicals, pharmaceuticals,  health-
care  and  food  processing  as  sectors  within  which  there  are processes  and 
products  of  special  potential  significance.  The  possibility of  gaining 
technology  transfer  from  innovative  U.S.  companies  is  noted. 
A comprehensive  major  policy document  is planned  to appear  by  mid-1983, 
outlining  a  development  plan  for  Irish biotechnology.  Focussing  on  pure 
and  applied  biological  research  and  on  industrial  needs,  it is the product 
of  close  Liaison  between  the  NBST  and  the Irish Development  Authority. 
The  Ministry of  Coordination,  in  consultation with  the Ministries of 
Science and  Technology,  Education  ancl  Agriculture,  is currently 
developing  plans  to stimulate awareness,  education  and  application of 
biotechnology.  This  will  be  developed  on  the  country's existing 
university groups  in  biology,  chemistry  and  agriculture - particularly 
using dairy  industry and  viticulture expertise - and  the national 
research  institute N.R.C.  Demokritos. 
In describing the  response  of  the member  states of  the  European  Community 
to the  challenges of  biotechnology,  it is relevant  to  consider the pri-
vate sector  commercial  activities,  and  the  public  policy initiatives 
including  education  and  publicly-funded  research  ;  but  no  less  relevant 
to the  co-ordination of  responses  is the  individual  and  voluntary effort 
which  finds  expression  through  professional  societies and  federations 
(see  box). - 51  -
Most  relevant  to  biotechnology  in  Europe  is the  European  Federation 
of  Biotechnology,  founded  in  1978.  It  includes  both  the  basic disciplines-
biologists,  biochemists,  microbiologists,  chemical  engineers,  and  appli-
cation areas  such  as  fermentation  and  public  health  engineering.  Through 
specialized  working  groups,  it brings  together multi-national,  multi-
disciplinary groups  on  such  topics  as  the  following  : 
- Education  for  biotechnology. 
- Standard methods  for  the  evaluation  of  bio-reactors, 
and  bio-reactor  standards. 
- Immobilized  biocatalysts. 
- Cell  culture  technology. 
- Environmental  biotechnology. 
- Safety  in  biotechnology. 
The  EFB  Newsletter,  the activities of  the  working  groups 
(several  of  which  are  preparing  reports),  and  the  support  of 
the  EFB  for  major  conferences  such  as  the  European  Congresses 
of  Biotechnology  (Interlaken,  1978  ;  Eastbourne,  1981)  can 
contribute significantly to  the  strength  and  self-awareness of 
European  biotechnology,  based  on  the  broad  networks  of  its 
member  societies. 52 
Re5ponses  of  the  European  scientists, via  voluntary and  professional 
associations,  to the  challenges of  the  life sciences and  biotechnology. 
long-established federations  in the three tasic disciplines  : 
the  Federation of  European  Microbiology Societies  (fEMS) 
the  Federation of  European  Biochemical  Societies  (FEBS) 
the  European  Federation of  Chemical  Engineering  CEFCE) 
Colloboration through  the 
European  Molecular  Biology  Organisation  (EMBO)  has  led to the creation 
of  the 
European  Molecular Biology laboratory,  ~eidelberg - a  successful example 
of  European  collaboration.  Similar to  EMBO  in concept  is ECBO  :the 
European  Cell Biology Organisation  (1st  Congress in Paris, July 1982, 
a  major  success>. 
For  collaboration on  school  and  university teaching of biology,  end  wider 
_ocial  questions,  ECBA  : 
European  Communities  Biologists Association. 
For  special  support  needs,  particularly on  culture collections  :  the 
european  Federation of  Cell  and  Virus  Collections, and  the 
European  Culture Collection Curators'  Organisation 
have  recently been  formed  (1981,  1982) 
In  the  application areas,  there are active and  effective groups  :  e.g. 
EGCA~PIA,  the  European  association of plant  breeders,  ~ith ita 
• 16  t·pecialiat  working  groups  and  aub-gruups;  and  the  European 
Aescciation  for  Animal  Production, 
whose  9  study  groups  have  just produced  a  long-range  assessm~nt of 
"Livestock  Production  in  Europe"  (Elsevier).  Useful  communication  centres 
for  European  industry are  CEFIC  (European  Association  of  Federations of 
the  Chemical  Industries>,  CIAA  (Council  of  the  Agro-food  Industries>, 
EFPIA  (European  Federation  of  Pharmaceutical  Industry Associations>,  as 
well  as  more  specialist  groups  <e.g.  AMFEP  :  Association of Microbial  Food 
Enzyme  Producers). 
~Major focus  for  biotechnology  in  Europe  is the 
i 
c~ROPEAN FEDERATION  OF  BIOTECHNOLOGY, 
four_ied  1978,  li:1king  over  40  learned  societies,  supported  by  ca.  10 
sp(cialist  working  groups,  and  organised  by  the 3  secretariats  : 
DECHEMA  (frankfurt> 
Society of  Chemical  Industry  (london) 
Societe de  Chimie  I~dustrielle (Paris) -53  -
4.  ~XISTING AND  PROPOSED  COMMUNITY  PROGRAMMES 
4.1.1.  The  manner  in  which  the  Community  has  acquired  research 
programmes  containing  aspects  of  Life-science  and  biotechno-
logy  may  be  described  as  gradual.  This  reflects the  range  and 
pervasiveness of  biotechnology across  the various  areas of 
responsibility of  the  Commission,  and  the  fact  that  the 
various  programmes  have  been  individually approved,  each 
for  specific  reasons,  rather  than  having  been  conceived  as 
elements  of  any  more  embracing  plan  for  biotechnology  research. 
Nevertheless  there  has  been  some  cross-support  between  them  and  they 
provide  a  significant  point  of  departure  in  considering  future 
developments. 
4.1.2.  Succeeding  sections of  this chapter describe  some  of  these 
programmes  or  sub  programmes  in  more  detail,  but  the  following 
listing gives  an  indication of  the  range  of  Commission  scientific 
activities which  are  involved 
•  Energy  research  - solar  energy  research  programme, 
project  E  biomass  as  an  energy  source, 
project  D  photobiological  mechanisms  to split water 
to  produce  hydrogen 
•  Radiation  Biology  programme 
•  Medical  Research  Programme 
•  Environment  & Raw  Materials  programmes  have  included 
potential  of  fermentation  hydrolysis  of  organic  wastes  ; 
wood  as  a  raw  material • 
•  Cost  programmes,  exchange  of  information  on  eg.  Sewage 
sludge  treatment  & disposal  methods  ;  studies of  single 
cell  protein,  early  weaning  of  piglets,  plant  tissue 
culture,  derivation of  animal  feedstuffs  from  ligno-
cellulose. - :54 
•  Agricultural  research  programmes,  including  land  use  and 
rural  development,  mediterranean agriculture,  treatment 
of  wastes  from  intensive agriculture,  animal  pathology, 
livestock productivity,  biological pesticides, plant 
improvement,  outlets for  products  in surplus,  tree 
diseases,  enhanced  production of  vegetable proteins  • 
•  Science & Technology  for  Development  ;  including tropical 
agriculture, medicine,  health  and  nutrition  • 
•  Databanks  such  as  EURONET-DIANE  arising  from  Community 
programmes  on  information  and  documentation  in  science 
and  technology are  helping  many  areas of  life science 
and  related  industrial  products  and  environmental  concerns 
to develop their  information  bases. 
4.1.3.  Many  other areas are touched  by  biotechnology;  for  example 
the  Commission's  industrial  or  economic  responsibilities for 
harmonisation of  standards  and  regulations  require the  conside-
ration of  products,  processes  and  terminology  in  industries 
such  as  animal  rearing,  food  processing  and  pharmaceuticals. 
4.2.1.  Objectives. 
Of  a  different  nature  to the  foregoing,  having  a  Longer  term 
strategic  intention,  is the  Biomolecular  Engineering  Programme, 
which  was  the  outcome  of  several  years  of  reports  and  consulta-
tions  with  industrial,  academic  and  government  interests. 
The  general  objectives of  the  programme  are  to  promote  and 
stimulate the  development  of  new  technologies  Leading  to 
.  the  manufacture  of  improved  agricultural  and  bio-indus-
trial products, 
•  the determination  of  more  efficient  and  safer production 
methods, 
to  be  achieved  through  the  removal  of  the  bottlenecks  which 
prevent  application  to  industry  of  modern  biochemical  and 
genetic  methods. - 55  -
4.2.2.  Phase  I. 
The  programme  is to  have  two  distinct  phases,  the first 
consisting  of  both  training  and  research  actions  and  having 
a  budget  of  8  MioECU.  The  trainina  will  cover  all  areas  involving 
enzymatic  and  genetic  engineering,  and  the  improvement  of  risk 
assessment  methods  so  far  as  agricultural  and  industrial appli-
cations of  biomolecular  enginnering  are  concerned.  The  research, 
using  shared  cost  contracts,  concerns  the  application of  modern 
biochemical  and  genetic  methods  to agriculture and  to agro-food 
production  and  will  include 
•  development  of  2nd  generation  bio-reactors  (multi-enzyme, 
multiphase,  etc ••  ~)  for  agro-food  industries 
•  improving  production,  via  biomolecular  engineering methods, 
of  safer  substances  for  animal  husbandry  and  the  agro-food 
industry  (there  is a  Link  with  the Agricultural  Research 
programme  :  see  section 4.3) 
•  Upgrading  of  plant  products,  particularly  Ligno-cellulose, 
by  means  of  biomolecular  engineering methods.(Link  with 
Raw  materials  sub  programme  on  wood,  see  4.5) 
•  Methods  for  identification,  transfer,  expression  and 
transmission of  new  genetic  information  in  cultivated 
plant  species  (Link  with  sub  programme  on  wood,  and  with 
Energy  and  Agriculture  research  programmes) 
•  Improvement,  by  means  of  genetic  engineering,  of  symbiotic 
relations  between  cultivated  plant  species  and  micro 
organisms  in  the  soil 
•  Development  of  methods  making  possible the  selective 
screening  of  cells and  protoplasts,  and  their  regeneration 
into fertile and  differentiated plants 
.  Improvement  of  methods  for  assessing  the  risks  which  may 
result  from  the  experimental,  industrial  or  agricultural  use 
of  genetically manipulated  micro  organisms. -56 
4.2.3.  Phase  2_. 
The  second  phase  will  retain  training  and  mission  oriented  research 
designed  to  allow  the  exploitation  by  agriculture  and  industry  of  the 
materials,  methods  and  konw-how  developed  in  the  field  of  molecular 
biology.  In  view  of  the  very  high  demand  for  funding  which  was  regis-
tered  during  the  first  phase  and  of  the  need  to  consolidate  the  actions 
now  in  progress,  only  few  modifications  have  been  made,  for  the  second 
phase,  to  the  programme  of  the first  phase.  Research  actions  in  genetic 
engineering  will  continue  to  be  restricted to plant-breeding,  animal 
husbandry,  agro-food  and  the  transformation  of  agricultural products 
They  will  include,  however,  the  use  of  biomolecular  engineering  methods 
for  the  early detection  of  genetic  changes  in  cultivated plants. 
Research  actions  in  enzyme  engineering  will  be  extended  to detoxifica-
tion  and  to  the  complete  range  of  industrial  applications.  Work  on 
safety  shall  be  focussed  upon  the  development  of  methods  for  detecting 
contamination  and  for  the  assessment  of  possible  risks  associated  with 
applications  of  biomolecular  engineering  in  agriculture  and  industry. 
Training  will  cover,  as  in  the  first  phase,  all  areas  involving  enzy-
matic  and  genetic  engineering. 
The  objectives of  the  Common  Agricultural  Policy  have  been  supported 
by  the  related  research  programmes  of  which  the  second  is nearing 
completion.  This  is a  5-year  programme,  1979-83,  18,6 m.u.a.,  with 
the  following  objectives  : 
A.  SOCIO-STRUCTURAL  OBJECTIVES 
1.  Land  use  and  rural  development 
2.  Mediterranean agriculture 
3.  Wastes  from  agricultural  industry and  effluents  from 
intensive  animal-rearing. 
B.  REMOVAL  OF  OBSTACLES  TO  INTRA-COMMUNITY  AGRICULTURAL  MARKETS 
4.  Animal  pathology. -57  -
C.  PRODUCTIVE  EFFICIENCY 
5.  Improvement  of  productivity of  the  Community  beef  herd 
6.  Biological  and  integrated pest  control 
7.  Methods  and  means  to be  developed  to  improve  the  resistanc  of 
plants  to disease and  environmental  stress 
8.  Agro-food  (new  outlets for  surplus  products,  good  quality) 
9.  Dutch  elm  disease (pi lot  coordination  project  on  tree dise ses). 
D.  ALTERNATIVE  PRODUCTS  (EXPLOITATION  OF  FORAGE  CROPS) 
10.  Improved  production  of  vegetable  proteins. 
Following  the  success  of  these  projects,  a  third five-year  pro  ramme 
(1984-88),  with  a  proposed  budget  of  54  m.u.a.,  is now  under 
discussion  ;  the outline  programme  shown  in  Table  8  has  been  ap  roved 
by  the  Standing  Committee  on  Agricultural  Research. POLICY 
THEMES 
RESEARCH 
PRO-
G'R"AMMES 
PRIORITY 
SUBJECTS 
Table  8  PROPOSED  AGRICULTURAL  RESEARCH  FRAMEWORK  PROGRAMME  1984-1988 
I 
Utilization and  Conservation of 
Agricultural  Resources 
1.  Energy  in  Agriculture 
2.  Land  and  Water  Management  and 
Utilization 
Economy 
1.1.  Integrated  plant  protection  inclu-
ding  all useful  combinations  of 
biological,  genetic,  agronomic  and 
chemical  methods  for  the  control 
of  diseases  pests  and  weeds,  aimed 
at  systems  with  low  energy  input 
1.2.  Alternative  sources of  energy,  in-
cluding  solar  energy  in  protected 
crops  and  in other  farm  uses 
Production  and  Application 
1.3.  Biomass  production  including 
•  Industrial  uses  of  existing 
crops  for  energy  purposes 
.  Specialized  crops  including 
aquatic  crops 
•  Improved  photosynthesis 
.  Improved  use  of  by-products  of 
existing  crops 
1.4.  Biological  nitrogen  fixation 
2.1.  Land  resource  evaluation  including 
crop  mapping,  and  identification 
of  areas  of  high  suitability for 
production  of  specific  crops  in 
different  areas 
2.2.  Prevention of  soil erosion,  soil 
degradation,  orfanic  matter  con-
tent  and  maintenance  of  soil  fer-
tility 
2.3.  Water  management  and  utilization, 
including  drainage  reclamations, 
water  control,water  pollution 
avoidance  etc  ••• 
II 
Socio-Structural  Aspects 
3.  Regional  Problems 
4.  Agro-Food 
3.1.  Mediterranean Agriculture* 
Systems  and  methods  of  production 
- Sylva-pastoral  aspects  of 
extensive  Livestock  production 
- Irrigation 
Selected alternative products  of 
_regional  interest, e.g. 
- Tobacco  (incl.oriental  tobacco) 
- Fast  growing  forest  verieties 
in  mountainous  zones,  etc  •• 
3.2.  Other  regions 
3.3.  Integrated  rural  development 
(e.g.  Multidisciplinary  resource 
studies) 
4.1.  Food  quality 
•  Intensive  versus  extensive  pro-
duction  (crops  and  animals) 
•  Protected versus  unprotected 
crops 
4.2.  Selected  marketing  aspects 
*  In  addition  to  subjects of  exclusive 
Mediterranean  interest,  to  be  dealt 
with  under  this  heading,  research 
programmes  1,2,5  and  6  will  include 
specific  references  to other  subjects 
of  Mediterranean  interest  which  can  be 
more  effectively treated  in  a  wider 
context 
III 
Improvement  of  Plant  and  Animal 
Productivity 
5.  Cropping  Practices 
6.  Animal  husbandry 
5.1 • 
5.2. 
5.3. 
6. 1 • 
6.2 • 
6.3. 
More  efficient  agronomic  practi-
ces  <e.g.  optimization of  ferti-
lizer use,  bio-engineering  and 
plant  breeding  practices) 
Protein and  oil  seed  crops 
Other deficit  crops 
Factors  affecting  herd  profi-
tabil1ty 
•  Reproduction  (including  phy-
siology and  neurobiology) 
•  Genetics 
•  Nutrition 
Animal  pathology 
•  Strategic  research  on  emerging 
diseases 
•  Immune  mechanisms  and  disease 
protection 
•  Disease  occurence  and  cost-
benefit  analyses 
Animal  welfare 
•  Social  space  requirements 
•  Disturbed  behaviour  and  stress 
Source  Doc.  CPRA  45/VI/1981  (Rev.  2) - 59-
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4.4.1.  Objectives. 
The  aim  of  the  extension of  project  D is to  contribute  stu  ies 
of  how  to  improve  bioproductivity  in order  to optimise  net 
energy output  per  hectare,  involving  basic  photobiology  an 
physiology  as  related to productivity  in  species  chosen 
their  biomass  energy  productivity. 
There  are  three  areas  of  work 
•  understanding  factors  which  Limit  the  potential  of  th 
photosynthetic  system  for  energy  production 
•  understanding  the various  forms  of  stress  which  preve  t 
the  expression  of  this potential  in  the  field 
•  development  of  field oriented tests  for  easier  recogn  tion 
of  productive  plants  based  on  their  photosynthetic  ca  acity 
under  a  variety of  conditions. 
4.4.2.  Key  areas  of  work. 
Fundamental  work  needs  to  be  carried out  on  systems  chosen  on 
the  basis of  their suitability for  solving  the  particular  roblem 
under  study.  In  general  the  choice  is related  to the  form  f  the 
plant,  absence  of  inhibitors,  availability of  mutants,  reproduci-
bility of  growth,  etc ••  Key  areas  for  future  work  include  : 
•  Limitations  to  photosynthetic  efficiency  :  product  parti-
tioning,  photoinhibition,  protective mechanisms  and  her 
wasteful  processes 
•  genetic  and  hormonal  control  of  photobiological  reactions 
•  membrarae  composition  and  st  ruct ural  changes  brought 
by  temperature,  water  and  nutritional  stress 
.  tissue  culture,  alternative  methods  of  propagation 
speeding  up  development  and  stabilisation of  the  gen 
characteristics of  potential  biomass  plants 
•  the  basic  components  of  nutrient  cycling,  including - 60  -
the effects of  increased  removal  of organic matter  and 
depletion of soil nutrients which  could  result  from  larger 
scale biomass  plantations 
•  modelling  biomass  energy  sustems  and  the  influence of 
external  factors  upon  net  energy yields. 
4.5.1.  At  its meeting  of  17  May  82,  the  Council  of Ministers  agreed  a 
new  raw  materials programme  worth  54  MioECUS,  including  12  for 
forestry  studies. 
The  European  Community  depends  on  external  sources  to provide 
more  than  half of  its needs  in  wood  and  wood  products and  the 
objectives of  the  new  progr.amme  "Wood  as  a  renewable  raw 
material"  are 
to  increase the physical  and  economic  availability of 
wood  and  wood  products, 
to  reduce  the  cost  of  growing,  harvesting  and  processing 
wood, 
•  to upgrade  the quality and  value of  products, 
•  to promote  a  more  complete utilisation of  wood  and  wood 
residue. 
4.5.2.  These  objectives  have  been  translated into 6  broad  research 
areas of  which  two  are of  particular interest  in the field of 
Biotechnology  : 
1)  Wood  production. 
(including selection and  improvement  of  forest  reproductive 
material,  improvement  of  growth  (silviculture),  prevention 
of  losses and  forest  inventory).  Contracts under  this  heading 
may  amount  to 1  MioECUS. 
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6)  Wood  as  a  source  of  chemicals. 
(including  development  processes  to separate  chemically the 
main  components  of  materials  containing  Ligno-cellulose 
substances,  the utilisation of  Lignin,  hemicelluloses  and 
cellulose,  and  the  recovery  of  by-products  from  fibre 
processing).  The  cost  may  again  be  of  the order  of  1  MioECUS. 
4.6.1.  Objectives. 
European  Community  policies  in  the  field of  Development  have  in 
the  past  concentrated  primarily upon  infrastructure and  agri-
culture.  However,  there  has  in  recent  years  been  growing  emphasis 
upon  the scientific  component  in  the  economic  and  social  deve-
Lopment  process.  An  R & D programme  proposal  has  therefore  been 
developed  which  seeks  to  complement  existing  Community  policies 
on  co-operation  with  developing  countries  and  to  reinforce the 
activities of  Member  States  in  their scientific and  technical 
potential  for  research  of  likely  benefit  to the  economic,  social 
and  health  development  problems  of  the  Third  World. 
4.6.2.  There  are  two  subprogrammes.  The  first  (A)  relates  to tropical 
agriculture,  and  includes  areas  where  biotechnology  and  related 
disciplines  have  great  potential, particularly in  the  light  of 
recent  developments  in areas  such  as  plant  cell  biology or  in  the 
fermentation  techniques  by  which  the  protein  content  of  carbohy-
drate  foodstuffs  can  be  enhanced.  The  sub-programme  includes 
these activities: 
A.1.  Improvement  of  agricultural  production. 
Food  crops  (esp.  rice,  maize,  sorghum) 
industrial  crops  <esp.  cotton,  ground  nuts,  soya, 
coconut  palm,  oil  palm) 
protein  products  of  animal  origin. - 62  -
A.2.  General  areas of  research  and  utilisation of  the 
environment. 
Water  resources  and  use 
soil protection,  stabilisation and  regeneration 
crop protection. 
A.3.  Post  harvest  techniques. 
Product  conservation 
processing of  products. 
A.4.  Training. 
4.6.3.  The  second  sub  programme  (B)  concerns  tropical  medicine,  health 
and  nutrition. 
8.1.  Medicine  and  Health  Care. 
Transmissible diseases  (involving  parasitology, 
bacteriology,  virology) 
Mother  and  child  care  (esp.  gastroenteritis) 
Genetics  (host  factors  affecting  susceptibility, parasite 
and  vector genetics,  control of genetic  disorders  with  high 
prevalence) 
Environmental  hygiene. 
8.2.  Nutrition  (esp.  overall  protein,  energy and  iron 
deficiencies). 
8.3.  Training  (two  way  mobility). 
4.7.1.  Two  concerted  action  programmes  have  been  agreed,  and  a  recently 
proposed  third one  is under  consideration * 
* see  COM  (81)  517  final - 63  -
The  first  two  dealt  with  the  following  issues 
1st  programme 
(1.1.1978-31.12.1981) 
2nd  programme 
(1.6.1980-31.05.1984) 
1.  Registration of  congenital 
abnormalities 
2.  Cellular  ageing 
3.  Extra-corporeal  oxygenation 
4.  Detection of  tendency  to 
thrombosis 
5.  Hearing  impairment 
6.  Perinatal  monitoring 
7.  Quantitative electrocardiography. 
4.7.2.  The  proposed  third programme  continues  and  integrates  the 
actions of  the  first  two  programmes  as  appropriate,  and  develops 
new  themes  within  three  sub  programmes 
•  Health  problems 
Area  1 
Area  2 
Area  3 
Pre,  peri  and  post-natal  care  (to  include 
chromosome  analysis) 
Ageing,  disabled  and  handicapped  (including 
cellular and  sub  cellular studies) 
Breakdown  in  adaptation 
•  Health  Resources 
•  Personal  Environment. 
Summarising  these diverse  programmes  from  the  point  of  view  of 
biotechnology,  one  can  make  three  points  : 
- the  programmes  generally  have  specific,  practical objectives 
and  can  be  classified as  "biotechnology"  only  under  a  broad 
definition  ; - 64  -
-many of  them  nonetheless  depend  upon,  or will  be  greatly 
assisted by,  progress  in  the  core  areas of  biotechnology and 
genetic  and  enzyme  engineering  ; 
- the one  programme  which  directly addresses  these  basic  needs, 
the  Biomolecular  Engineering  Programme,  at  4  m.u.a.  for  its 
first  two  years  is on  a  very  modest  scale  in  relation  to 
the needs. 
5.  MEDIUM-TERM  OPTIONS  AT  COMMUNITY  LEVEL  THE  NEED  FOR  STRATEGY 
The  European  Community  can  and  should  have  a  major  influence upon 
the  development  of  biotechnology  in  Europe.  In  the  following  section 
are  summarized  the aspects  which  indicate this need  for  coordination 
and  a  European  policy role.  If this "positive" option  is  not 
exercised,  then  it may  reflect  a  judgement  by  at  Least  the  larger 
countries of  the  Community  that  they  are  big  enough,  are doing 
enough,  and  their major  firms  can  collaborate as  necessary  with 
centres of  expertise or  strong  firms  elsewhere  - particularly in 
the  U.S.  and  Japan.  In  the  public  sector,  policy-makers  in each 
Member  State,  operating  on  similar  evidence,  under  similar pressures 
and  in  similar positions,  will  make  similar decisions.  Therefore 
when  the  available opportunities are  ranked  in order  of  attractive-
ness,  the  same  top  choices  will  be  selected,  the  same  secondary 
topics  will  be  neglected.  With  only  slight exaggeration,  one  can 
envisage  a  scenario  in  which  : 
everybody  will  attempt  Nitrogen  fixation 
-everybody will  (relatively)  neglect  culture  collections 
-everybody will  pursue  monoclonal  antibodies  and  immunology 
-nobody will  look  after  cryopreservation  and  plant  cells 
every  farm  and  Ministry of  Agriculture will  pursue  maximum 
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genetic diversity,  disease  resistance  and  soil  science will  be 
neglected 
- industrial  research  laboratories  will  follow  the  well-beaten 
track  to E.col i 
-few will  embark  on  fundamental  studies of  microbial  physiology 
in  lesser  known  organisms. 
An  integrated view,  or  even  some  modest  co-ordination  between 
existing national  strategies,  would  produce different  answers.  But 
the  confidence  to  abandon  a  potentially promising  sector,  or  to 
spend  on  another  sector greater effort  than  would  be  merited  on 
purely national  criteria,  can  only  be  justified if there  is poli-
tical  confidence  in  a  Community  approach,  and  some  de  facto  sharing 
of  costs,  risks,  and  benefits at  European  scale. 
The  influence of  the  Community  will  be  exercised  both  through 
R & D policy,  and  through  its other  policies  :  for  maximum  effective-
ness,  they  should  be  mutually  reinforcing,  and  therefore  require 
coordination  by  the  Commission  of  the  European  Communities.  At  the 
same  time,  Community  policies  should  be  related  to  the  actions  being 
taken at  national  scale  by  member  states,  and  at  international  scale 
through  such  bodies  as  the  OECD  or  the  United  Nations  and  its agencies. 
Reference  is therefore  made  as  appropriate  to  these  international 
activities. 
ALL  the  national  studies  cited give  independent  confirmation of  the 
strategic  sign~ficance of  biotechnology,  a  significance  which  will 
persist  in  spite of  the  current  journalistic "over-selling".  It  is 
widely  recognized  that  the  quality of  a  nation's biotechnological 
capacities will  be  of  importance  for  its  Long-term  industrial  compe-
titive strength  in  several  major  sectors. - 66  -
The  external  challenge to the  Community,  from  its major  trading 
partners, will  be  a  strong one.  In  the  area of  public  sector support, 
it is clear that  the U.S.  will outspend  the  European  Community  in 
total, particularly in all areas  related to medical  applications. 
Table  9  brings  together  the  figures  presented  in the earlier chapters. 
The  Japanese,  through  the  Science and  Technology  Agency  as  well  as 
through  the Ministries  (MITI,  Agriculture  and  Health),  although 
spending  less  than  the  EC  in total, appear  (on  past  form>  to be 
likely to achieve more  effective  coordination of  industrial strategy. 
The  pharmaceutical  industry  is the subject  of  intense current deve-
lopments,  but  is only one  sector  in  which  capability in  the  life 
sciences will  be  reflected. 
Table  9  :  A ROUGH  SUMMARY  COMPARISON  OF  PUBLIC  SECTOR  R & D 
EXPENDITURE  RELATED  TO  BIOTECHNOLOGY 
U.S.A.  (! M = m.u.a.) 
National  Institutes of  Health  90  (out  of  S  3  - 4  bn  on  health 
National  Science  Foundation  60 
U.S.  Dept  of  Agriculture,  Office 
of  Technology  Assessment 
Dept  of  Energy,  etc ••.  ? 
zoa 
Life  sciences total  expenditure  195 
including  biotechnology  22 
add.  MITI  special  programmes  10 
and  related  ;  cf  1,8 bn  for 
EC  - see Table  6) 
(cf  EC  385  i.e. twice as  great  -
see  Table 6). 
32  +  industrial  grants 
European  Community 
Biotechnology  expenditures 
F.R.  Germany 
France 
U.K. 
lt<:dy 
22  (project)  +  7  (institutional) =  29 
29 
43 
13 
+  other  EC  countries  ? 
EC  Biomolecular  Engineering  Programme  :  4  p.a. 
?  130  +  in1ustrial 
~rants 
(Figures  for  current  or  recent  years,  with  many  potential  pitfalls 
of  comparability, definition,  coverage,  etc •• ). - 67  -
For  Europe  to  respond  effectively to this  challenge,  there  must  be 
developed  a  "holistic" view  of  the  nature of  capability  in  bio-
technology,  overcoming  the  several  dimensions  of  potential  fragmen-
tation  : 
- National  efforts  require  co-ordination  within  the  Community  ; 
-different disciplines  have  to work  together  ; 
- "pure"  and  "applied"  scientists and  technologists  have  to  collaborate  ; 
-academic  knowledge  has  to be  transferred  to  industrial  application  ; 
- public  and  private sector efforts  have  to  be  complementary. 
The  need  for  coordinated efforts  is  illustrated by  the  behaviour  of 
the  major  companies,  where  even  the  largest  - several  of  them  spending 
more  on  biotechnology  R & D than  national  research  budgets  in  the  field 
see  the  need  for  collaborative and  consortial activity,  to  spread  the 
risks  and  costs.  This  is all  the  more  true  for  the  Longer  term  funda-
mental  research  financed  by  governments. 
At  national  and  Community  Level,  the  need  is  perceived  for  research  and 
development  work  variously described  as  "strategic- applied", 
"pre-commercial"  and  "Long-Lead-time".  Normal  commercial  incentives 
will  drive  short-term  innovation,  but  strategic  strength  rests  on  a 
relatively  Large  number  of  fundamental  disci~Lines or  capabilities. 
These  will  not  generally or necessarily arise  if their development 
depends  on  short-term economic  criteria.  The  key  capabilities  include 
genetics  (molecular  and  classical),  physiology,  biochemistry,  fermen-
tation and  culture technology  (from  Laboratory  industrial  scale),  and 
all aspects  of  process  technology  ;  all of  the  disciplines  being 
understood  as  including microbial,  plant,  animal  and  hybrid  materials. -68  -
World-class  capability  in all of  these  fields  is not  a  realistic 
objective  for  any  one  member  state of  the  European  Community  ;  it must 
be  an  objective  for  the  Community  as  a  whole.  Europe  must  reinforce 
or develop  a  limited number  of  strong  centres,  in existing universities 
and  research  institutes. 
Each  such  centre  (or  polycentric  consortium)  should  aim  to  be  of 
unsurpassed  quality within  its field,  based  on  experienced staff and 
the best  physical  equipment  and  facilities.  Its activities will  typi-
cally  include  teaching,  research,  advisory  consultancy,  contract  work, 
and  possibly pilot  plant  and  production  activity.  It will  represent, 
not  only within  its country  but  throughout  Europe  and  further afield, 
a  natural  point  of  reference  for  academic,  industrial or  other enquiries. 
Complementary  to  the  individual disciplines  represented  in  the  centres, 
and  no  less essential  to their effectiveness,  is  the ability to  form 
and  manage  inter-disciplinary teams  :  focussed  on  the  determined  pur-
suit of  a  clear and  sign~ficant joint objective.  The  major  successes 
of  biotechnology  have  depended  on  this  type  of  project  management  : 
penicillin production  is a  classic  example.  The  definition of  appro-
priate strategic priorities  could  be  a  matter  for  joint discussion 
involving  member  state policy-makers,  industry and  academic  experts, 
and  Community  staff  :  several  possible  foci  for  such  activity are 
offered  in  5.5  and  5.6 below. 
The  commanding  heights of  biotechnology are  likely to be  dominated  by 
a  Limited  number  of  multi-national  companies  ;  technologically  sophis-
ticated,  with  strong  current  positions enabling  them  to  invest  on  a 
large  scale  in  areas  of  Long-term  future  potential.  These  companies 
will  have  R & D  centres  in  several  countries,  manufacturing  (or  service) 
locations  in  more,  and  marketing activities almost  everywhere.  They 
will  have  effective  freedom  to shift  the  centres of  gravity of  their 
R &  D  and  other operations  from  country  to  country  and  continent  to 
continent,  in  response  inter alia  to  the  conditions,  the  resources  and 
needs,  opportunities  and  constraints,  in  each  location. -69 
Biotechnology activities will  be  influenced  by  the  following  factors 
- Feedstock availability  and  cost  ; 
- human  resources  ; 
supporting  services  and  facilities  ; 
- regulatory environment. 
ALL  of  these  can  be  influenced  by  public  policy,  at  national  and/or 
Community  level. 
5. 4.  Feedstocks  -- .... ~  .... -----
Locally  available  feedstocks  are  Likely at  present  to  be  channelled 
through  existing  and  traditional activities,  institutions and  struc-
tures,  such  as  the  agriculture and  agro-food  system.  These  are 
encouraged  to  defend  themselves,  by  productivity  improvements, 
rationalization,  adding  more  value  to  the  materials.  They  may  either 
develop  biotechnology  themselves,  or  their ability to  supply  to  bio-
technology.  Since  the  prices of  agricultural  commodities  are  controlled 
by  the  Common  Agricultural  Policy,  this  is one  point  of  influence  for 
Community  policy. 
Human  resources  are  developed  primarily  through  national  education 
systems,  at  Least  in  their  foundations.  At  more  advanced  Level,  public 
research  policies  can  influence  the  availability of  research  posts  in 
universities and  public  institutes.  Finally,  the  experience  in  both 
productive  industry  and  indust~ial  research  Laboratories  adds  greatly 
to  the  value  and  potential  of  the  individuals  concerned.  In  a  multi-
disciplinary field  such  as  biotechnology,  the  experience  of  working 
within  multi-disciplinary project  teams  is also  a  vital  aspect  of 
education.  In  many  national  environments,  including  even  the  Largest 
countries  of  the  European  Community,  there will  not  be  full  opportuni-
ties for  specialists to  develop  experience  in all  respects  of - 70  -
biotechnology  ;  there  is  consequently  a  need  for  international 
exchange  of  individuals,  particularly to  the  "key  centres"  referred 
to. 
The  economics  of  mounting  advanced  level  study  courses  also demand 
their organization  and  promotion  on  a  larger  than  national  scale, 
again  based  on  the "key  centres". 
Amongst  the  supporting  services  crucial  for  biotechnology,  the most 
important  is the  human  resource,  already  mentioned.  One  might  add 
also  the availability of  process  plant  and  instrumentation,  and  the 
accompanying  expertise.  But  a  specifically biological  resource  is the 
genetic  material  itself -micro-organisms,  plant  and  animal  cells. 
This  subject  is not  only  important  in  itself, but  in  its diversity, 
complexity  and  "information  intensity",  illustrates  some  of  the 
general  characteristics of  support  services  in  an  "information 
society". 
The  importance  of  culture  collections of  micro-organisms  and  of  other 
biotic material  (e.g.  plant  cell  Lines  and  germplasm,  animal  cell 
Lines,  viruses,  plasmids,  enzymes  •..  )  is being  increasingly perceived 
as  an  essential  foundation  for  both  academic  and  industrial  research 
and  exploitation.  The  accumulation  of  research  results  and  under-
standing of  these  complex  entities  is generating vast  quantities of 
potentially useful  information,  which  demands  the  organized  storage  and 
retrieval facilities of  computer  databanks.  The  technologies  of  storage 
demand  considerable  expertise,  and  for  many  organisms  are not  yet  fully 
understood,  so  that  industrialists and  researchers still frequently 
lose  their  stored  cultures  (through  death  or denaturation).  The  relevant 
know-how  is not  prestigious,  and  even  in  those  countries  well  endowed 
with  collections,  continuing  budgetary  and  technical  support  is  in  many 
cases  problematic  and  uncertain. - 71  -
Perceiving  this  problem,  the  British  and  Germans  are  seeking  to develop 
a  collaborative policy  for  their  collections.  The  Pelissolo  report  has 
emphasized  the  French  needs,  and  other  countries of  the  Community  also 
share the  perception  of  this need.  Danish  scientists  have  participated 
in  work  organized  by  the  Nordic  Council  on  a  register of  culture 
collections.  At  world  level,  UNESCO  finances  a  "World  Data  Center" 
in  Brisbane,  Australia,  which  has  just published  the  second  edition 
(1st  was  in  1972)  of  a  World  Directory of  Collections of  Cultures of 
Micro-organisms  (with  some  financial  support  from  the  European 
Commission). 
Within  Europe,  policy for  c~lture collections  is  being  helped  by  the 
formation  (first  meeting  May  1982)  of  the  European  Culture  Collection 
Curators'  Organization  (ECCCO),  and  the  European  Federation  of  Cell 
and  Virus  Collections  (EFCVC).  Specialists  in  plant  cells and  plant 
tissue culture  techniques  have  also  been  approached  by  the  initiators 
of  EFCVC  (whose  primary  interests are  human  and  animal  cell  Lines  and 
viruses).  Plant  tissue conservation  interests are  also  supported  by 
the  International  Uoard  for  Plant  Genetic  Resources  of  the  UN  Food  and 
Agriculture Organization. 
These  activities  can  be  helped  by  coordination  and  support  as  necessary, 
at  Community  level,  particularly through  the  Task  Force  for  Biotechno-
Logy  Information,  which  reports via  the  Biomedical  Working  Group  to  the 
Commission  on  Information  and  Documentation  in  Science  and  Technology. 
Within  the draft  Work  Programme  of  this group,  mention  should  particu-
Larly  be  made  of  the  coordination  of  European  development  work  on 
nucleic  acid  (DNA  or  RNA)  sequence  data  banks  :  a  perfect  example  of 
a  topic  of  fundamental  importance  for  future  work  in  the  Life  sciences. 
The  European  work  at  several  centres  (EMBL  Heidelberg,  Lyon,  Sari, 
Cambridge)  is significant,  but  there  must  be  effective coordination  to 
develop  capabilities which  can  co-operate on  a  basis  at  least  of  parity 
with  the  U.S.  work,  now  being  strongly  pursued  by  the  NIH  (reference 
was  made  in  2.2.1  to the  Z 3.2  m.  contract,  June  1982). - 72  -
Industry operates  simultaneously  in  many  regulatory  environments, 
which  the  Community  is  seeking  to  harmonize  at  Least  within  the  member 
states  :  product  standards,  pharmaceutical  testing,  feedstuff  additives, 
and  food  additives are  examples  of  areas  where  regulation  impinges  upon 
industrial  biotechnology. 
In  the  research  context,  the  Long  debate  on  the  conjectural  hazards  of 
re-combinant  DNA  work  now  appears  to  be  stabilizing,  with  the  relaxation 
of  guidelines  in  the  U.S.,  the  U.K.  and  elsewhere  following  recognition 
that  no  new  special  risks  have  appeared,  beyond  those  normally  encoun-
tered  where  the  organisms  used  are  known  pathogens.  The  Commission 
draft directive on  the  subject  has  been  Left  at  advisory  status. 
In  the  regulation  of  the  pharmaceutical  industry,  the  best  interests 
of  the public  require  an  intelligent  balance  to be  struck  between 
rigorous  pre-release testing,  which  increases  costs  and  delays,  and 
post-release monitoring.  While  seeking  harmonization  within  the 
Community,  the  Commission  has  to  seek  also  a  wider  acceptance  exter-
nally of  European  standards.  Reference  has  been  made  (2.2)  to  the 
coming  Liberalization of  Japanese  standards.  Other  countries  should 
also  be  encouraged  to  see  the  European  standards  as  no  Less  acceptable 
than  the  sometimes  very  conservative  standards of  the  U.S.  Food  and 
Drug  Administration. 
Forthcoming  studies  by  the  OECD  are  Likely  to  focus  upon  a  number  of 
public  policy  implications of  the  development  of  biotechnology  : 
particularly 
- patent  Legislation  (an  enquiry  has  been  Launched)  ; 
- regulations  ; 
-university- industry  Links. 
The  OECD  studies  will  undoubtedly  produce  useful  comparative  surveys. 
In  parallel with  these,  the  Community  has  a  role  to  play  in  coordinating - 73  -
the  European  response  on  questions  such  as  patent  Legislation,  in 
ensuring  that  any  international  conventions  established strike an 
equitable  balance  between  the  interests  involved~ The  difficulties 
are  illustrated by  a  fundamental  point  of  contention  which  has  arisen 
between  biologists/biotechnologists  and  traditional  patent  lawyers. 
The  former  may  screen  many  thousands  of  different  micro-organisms  to 
select  and  propagate  a  useful  mutant  ;  if  the  Lawyers  still call  this 
"discovery'',  it may  not  be  patentable,  since  the  ancient  principle  is 
that  only  "invention"  is  patentable.  Given  such  difficulties,  and  the 
problems  of  characterizing  an  organism  in  ways  which  will  define 
whether  one  is "identical" to  another,  commercial  firms  are  likely 
to protect  their  intellectual  property  by  secrecy  rather  than  patenting. 
Such  a  tendency  inhibits  the diffusion of  knowledge  which  is one  of 
the  fundamental  objectives of  the  patent  systems. 
Also  inhibiting  innovation  is  the  use  of  patents  as  blocking  mechanisms  : 
defending  intellectual property,  but  perhaps  preventing  the  exploitation 
of  the  process  in  certain  countries.  To  overcome  such  abuse,  conditional 
on  "permanent  diligence"  in  the  exploitation of  the  patent. 
A more  recent  role  of  the  patent  system  has  been  to provide  statistical 
information  on  patent  registrations  ;  subject  to various  caveats  a 
useful  indicator  of  the  innovative  strength  of  the  various  companies  or 
countries  in  each  sector. 
For  these  several  reasons, patents  are  a  subject  meriting  significant 
attention  at  Community  level  in  the  context  of  strategy  for  European 
biotechnology. - 74  -
Reference  has  been  made  (Section 3.3)  to the  SEDES  study of  the oppor-
tunities  for  small  and  medium-sized  enterprises  in  biotechnology. 
Several  studies of  biotechnology*  have  emphasized  its dual  nature 
"big"  biotechnology,  characterized  by  concentration,  capital  intensity, 
high  technology  and  economy  of  scale,  as  typified by  the  ICI  single-cell 
protein plant  ;  and  "small"  biotechnology,  based  on  local  resources  or 
wastes,  as  typified  by  biogas digesters at  farm  or Third  World  village 
Level. 
Most  studies  emphasize  that  there  is potential,,indeed need,  for  both  to 
exist.  The  presence  of  strong  centres  of  activity of  large  companies  will 
create opportunities  for  smaller  companies  as  suppliers;  the  existence of 
a  network  of  efficient  suppliers  creates  a  more  favourable  environment  for 
the  large  companies.  Community  policy  for  encouragement  of  innovation  and 
venture  capital activity  can  help  such  developments. 
In  developing  policy for  biotechnology,  the  Community  has  to  ensure 
that  the objectives of  the  common  R & D policy are  compatible  with 
and  supportive of  other  community  policies.  The  development  of 
biotechnology  in  Europe  has  interactions  with  each  of  the areas 
summarized  below. 
Economic  growth  - stimulus of  new  growth  sectors of  industry. 
Industry- sectoral policies  :  agrofood,  feedstuffs,  chemicals,  forestry 
& wood  products,  Leather,  textiles,  regulatory & patent  policies 
Education  - technical  and  scientific. 
Health  - fundamental  support  for  pharmaceutical  development, 
information  exchange  to  sup~ort societal  learning. 
Agriculture  - genetics of  plants  and  animals,  fertilizers,  growth 
promoters,  crop protection,  feedstuffs,  post-harvest 
protection. 
*  For  example,  "Impacts  previsibles et  strategies de  developpement  de 
La  biotechnologie  dans  les  filieres agro-alimentaires  europeennes 
cas  des  filieres proteiques",  study  by  Promotech,  in  the  FAST 
programme  of  the  CEC. -75  -
Development  - science  and  technology  for  development,  impact  of 
biotechnology  on  Third  World  and  commodity  trade 
patterns. 
Environment  - waste  treatment,  control  of  toxic  effluents,  emission 
and  quality  standards. 
Scientific  Information  - databanks,  culture  collections. 
Fisheries  - processing,  alternative protein  sources~ 
Energy  - biomass. 
This  "horizontal"  character  of  biotechnology  typically  creates  a  need 
for  corresponding  structures  to  coordinate  the  interactions  with  exis-
ting "vertical"  government  bodies  and  institutions  :  a  number  of  the 
Member  States  of  the  EC  have  created  inter-departmental,  inter-sectoral, 
i n  t e r-d i s c i p l i n a r y  "B i o  t e c h  no Logy  C  om m  i t t e e s"  o r  "rVJ i s s i on s"  t o  respond 
to  this  need.  Similar  measures  are  being  taken  within  the  services  of 
the  Commission  of  the  EC,  to  ensure  the  necessary  co-ordination of  diffe-
rent  policies- including  the  research policy,  discussed  in  the  final 
chapter. 
6.  RECOMMENDATIONS 
The  five  previous  chapters  have  attempted  to  illustrate the  challenge 
which  the  development  of  biotechnology  and  its  related disciplines 
poses  to  Europe,  and  to  compare  the  respons~ of  the  individual  Member 
States  and  the  Community  with  that  of  Europe's  coLlpetitors. 
Some  idea  has  clso  been  g1vcn  of  the  options  open 
to  Europe  in  the  medium  term.  It  might  also  be  useful,  before  setting 
out  some  specific  recommendations  in  the  field  of  biotechnology,  to 
recap  the  overall  objectives  which  influence  Community  Science  and 
Technology  policy.  These  are  summed  up  in  the  seven  major  goals 
defined  in  the  Framework  Programme: - 76  -
•  Promoting  agricultural  competitiveness 
•  Promoting  industrial  competitiveness 
•  Improving  the management  of  raw  materials 
•  Improving  the  management  of  energy  resources 
•  Strengthening  aid  to developing  countries 
•  Improving  living  and  working  conditions  (Health,  safety, 
the  environment) 
•  Stimulating the efficacy of  the  Community's  R & D potential. 
Biotechnology  is relevant  to every one  of  these goals,  as  is 
demonstrated  by  both  the  preceding  discussion  and  the  recommen-
dations  below. 
6.2.  Contextual  Recommendations  (non  R&D)  ------------------------------------
The  recommendations  which  have  arisen  in  the  context  of  strategy for 
European  biotechnology  repeatedly  lie outside the  specific  boundaries  of 
R & D policy.  The  following  recommendations  have  therefore to be  addressed 
to  the other  services of  the  Commission,  to  Member  States, and  other 
authorities as appropriate.  The  recommendations  have  as  their  common 
objective the  creation of  a  context  within  which  European  biotechnology 
can  be  successfully developed  and  exploited  : 
a.  B2~_m2!~[i~i_[~~2~££~~ :  should  be  available to  the  fermentation  or other 
biotechnology  industries, at  prices  <excluding  transport)  not  greater 
than  those  of  the  open  world  market.  This  measure  should  form  part  of 
a  financial  strategy  in  relation  to  improved  land  use. 
b.  tl~ffi2Q_[~~Q~[£~~  :  Member  States are  urged  to  consider the  quality and 
scale of  their educational  provision  in  the  fundamental  disciplines of 
the  life sciences  in  schools  and  universities  ;  and  the  specific  pro-
vision  for  training  in  biotechnology at  technician  and  at  post-graduate - 77  -
Level.  Member  States  and  the  Commission  are  urged  to  consider also 
specific  provision  to  facilitate scientific mobility  and  international 
exchange  in  biotechnology,  between  universities,  and  between  universi-
ties  and  industry  (e.g.  part-time  industrial  professors). 
c.  ~~ee~[!_~~r~i£~~ :  Member  States and  the  Commission  are  urged  to 
encourage  the  development  of  the  support  services  and  facilities  shown 
to  be  desirable  for  the  encouragement  of  biotechnological  industrial 
development.  These  could  include,  in  addition  to  the educational 
services  mentioned,  the  following 
- research  and  consultancy  services  ; 
- support  for  vocational  training  in  biotechnology - e.g.  for  the  pro-
duction of  audio-visual  materials,  including  general  public  education. 
bibliographic and  information  services  ; 
culture collections of  cells  and  micro-organisms  ; 
-small  and  medium-sized  firms,  for  supply  of  specialist  materials 
and  services  ; 
patent  advisory  service. 
d.  8~9~i~!i~Q~ : the  creation of  clear  and  consistent  regulatory  frameworks, 
applicable  throughout  the  Community,  on  all aspects  of  Laboratory deve-
Lopment,  factory  manufacture,  testing,  and  marketing  of  products  and 
services  ;  with  particular  reference  to  the  novel  products  and  services 
Likely  to arise  in  the  fuel,  food,  chemical  and  pharmaceutical  industries. 
In  view  of  the  strategic  significance of  biotechnology,  in  both  the 
products  it offers  and  the  new  industrial  technologies  it develops,  the 
regulatory  stance  should  (while  maintaining  normal  standards  of  public 
security)  be  neutral  or  favourable  ;  and  avoid  being  pressured  by  argu-
ments  of  doubtful  scientific  validity  towards  de  facto  defence  of  existing 
established  interests  against  competitive  innovation. - 7S  -
The  preceding  chapters  have  emphasised  the  significance  and  pervasive-
ness  of  the  applied  Life  sciences,  and  the  energetic  responses  by  compa-
nies  and  national  authorities  to  the opportunities presented  by  the 
recent  and  continuing  advances.  ALL  national  authorities  in  developed 
industrial  countries  acknowledge  the  need  for  public  research  programmes, 
particularly  in  fundamental  science,  and  in  the  areas  variously described 
as  "Long-Lead-time", "strategic applied"  or  "pre-commercial"  research. 
Table  9  suggests  the  intuitively  reasonable  picture that  Community 
total  spending  on  biotechnology  R&D  appears  to  be  at  a  rate  somewhat 
g r e at  e r  t h  a n J ap an 
1 s ,  L  e s s  t h  a n  t h  e  U  • S • A  • 
1 s  ;  1 n  bot h  c a s e s ,  t h  e  e f f or  t 
is  Likely  to  be  better  co-ordinated  than  within  the still fragmented 
environment  of  the  European  Community. 
In  presenting  below  a  collection  of  recommendations  for  Community  R&D 
in  biotechnology,  these  have  been  organised  into  three groups,  in all 
of  which  emphasis  has  to  be  placed  upon  enhancing  the  coherence  of  the 
European  efforts  : 
1.  as  a  stimulus  and  support  to national  programmes 
2.  in  support  of  other  research  and  action  programmes 
the  "interaction"  areas 
3.  for  pioneering  in  biotechnology. 
6.  3.  1. Community  R&D  as  a  stimulus  and  support  to national  programmes  and  centres 
The  case  for  joint  Community  R&D  action  is  a  familiar one- the  avoidance 
of  duplication,  the  pooling  of  major  expenses  or  of  scarce  resources, 
etc., but  points  of  particular  importance  in  the  context  of  biotechnology 
are  the  following  : - 79  -
a)  the  enhancement  of  the  value  of  national  programmes  through  the  oppor-
tunity to  compete  for  and  to  participate  in  Community  programmes 
(such  as  the diomolecular  Engineering  Programme).  Such  opportunities 
will  stimulate  standards  and  reinforce  the  strong  centres  around 
which  national policies  are  generally  based,  enabling  them  to  become 
in  some  senses  "European"  resource  centres. 
b)  the  enhancement  of  specialised  training facilities  by  providing 
opportunities  and  support  for  mobility  and  training;  these  form  part 
of  the  Biomolecular  Engineering  Programme,  and  are  a  feature  of  the 
"stimulation"  activity. 
These  stimuli  to  foundation  capabilities  in  the  Member  States  could 
also  be  seen  as  part  of  the  "contextual
11  effort,  whose  "non  R&D" 
aspects  were  introduced  above.  R&D  actions  to  enhance  the  context 
for  European  biotechnology  should  include  actions  : 
a)  in  support  of  culture  collections- see  for  example  references 
below  to  cryopreservation  of  plant  cells  and  tissues, 
b)  in  support  of  the  nucleic  acid  sequence  databank  at  the  ~uropean 
Molecular  Biology  Laboratory, 
c)  research  into  taxonomic  aspects  and  information  requirements  of 
information  systems  associated  with  collections  of  biotic material 
<culture  collections,cell  and  tissue  banks,  seed  banks,  ••• ) 
6.  3.  2. Community  R&D  through,  or  in  support  of, other  research  and  action 
programmes  :  the  ''interaytion"areas 
The  cross-cutting  nature  of  biotechnology  is  illustrated  by  considering 
the  following  current  or  proposed  research  or  action programmes,  to 
which  the  Biomolecular  Engineering  or  other  specifically "biotechnology" 
programmes  can  contribute significantly;  we  term  these  the  interaction 
areas.  Details  have  been  given  in  Chapter  4  : - 80  -
- agricultural  research 
- raw  materials- starch,  sugar,  wood  etc  •• ,  fermentation 
hydrolysis  of  organic  wastes 
- biomass  energy 
- environment  programmes 
- medical  research 
- radiation  biology 
- science  and  technology  for  development  (tropical 
agriculture,  health  and  nutrition) 
- several  of  the  COST  programmes  :  particularly those  on 
single-cell protein;  plant tissue  culture;  feedstuffs 
from  Ligno-cellulosic  wastes;  and  sewage  sludge  treatment 
(now  incorporated  in  the  environment  programme). 
Of  particular  importance  is the  interaction with  agriculture,  the  sector 
in  which  the  Community  policy  role  has  for  Long  been  of  major  signifi-
cance.  Community  R&D  can  play  a  positive  role  in  developing  cost-effec-
tive  ways  of  exploiting  agricultural  resources.  While  this  can  include 
research  into  new  uses  for  products  currently  in  surplus,  the full 
exploitation of  the potential  of  the  new  biotechnology  implies  : 
- efforts  to  reduce  production,  storage  and  distribution  costs,  and  thus 
to  increase  the  competitiveness  of  European  agriculture. 
-upgrading  the  qu-ality  of  agricultural  products 
- rather  than  increasing  production of  products  in  surplus,  extending 
the potential  for  economic  production of  materials  currently  in 
deficit. 
In  short,  expanding  the  range  of  economically  viable  and  technically 
feasible  uses  for  Land.  This  interacts  strongly  with  the  Agricultural 
Research  Programme  (see  section 4.  3, Table 8);  but  requires  also  indus-
trial  R&D  (e.g.  in  food  processing  or  agricultural  machinery);  and  will 
benefit  from  the opportunities  created  by  progress  in  the  fundamental 
sciences  (see  following  section, 6.  3. 3.). - o1  -
What  is needed  is an  integrated  approach  to 
E!~D!_9~D~!if~~-r~Ei2_!~E!iE~!iQD_!~fbDi9~~~~-E1~D!_Q~!ri~D!_~E!~~~ 
~t2!~~2~-~b2!~_f£QE_b~r~~2!iD9-~D2_iD!~9!~!~2-1~D2_~~D~9~~~D!_~t2!~~2· 
The  relevant  research  activities  range  from  the plant· genetics of  the 
8iomolecular  Engineering  Programme  to the  integrated  Land  use  studies 
of  the  Agricultural  Research  Programme. 
Research  planning  has  to  integrate, or  at  Least  coordinate,  the targets 
for  crop  breeding,  machinery  development  and  other on-farm  downstream 
processing  techniques  (see  below).  Such  a  "total  systems  approach''  will 
Lead  to  widely  varying  solutions  in  the different  Land  and  climate 
conditions  of  different  regions  of  the  Community,  but  will provide  a  basis 
of  understanding  in  depth  and  organised  knowledge,  which  will  in all 
those  regions  provide  greater  adaptive  capability,  both  tactical  and 
strategic. 
6.  3.  3.  Community  R&D  for oioneering  in  biotechnology 
The  Community  R&D  policy  can  provide  support  for  national  programmes, 
can  improve  the  context  for  European  biotechnology,  and  can  support 
related policy objectives  such  as  the "interaction"  areas  described 
above.  Reference  has  been  made  in particular to  what  may  be  termed 
a  "vertical"  role,  support  for  the  specific  sector  of  agriculture 
the general  objective being  the  creation of  a  Less  costly  Common 
Agricultural  Policy,  without  reducing  farm  incomes. 
There  are other  sectors  in  which  such  vertical,  sectoral  support  is 
equally  appropriate.  For  example,  the pharmaceutical  industry, 
a)  because  of  the particular  relevance of  biotechnology; - 82  -
b)  because  of  the prospect  of  strategic  competitive  challenge  (see 
section 2.3.  above); 
c)  because of  the  high  and  growing  costs of  illness, its prevention  and 
cure;  in  both  the developed  countries  and  the Third  World.  There 
are  widespread  needs  - e.g.  for  an  influenza vaccine - where  the  current 
structure of  incentives  is not  necessarily  leading  to the  Lowest 
total  costs, and  where  a  Community  initiative could  be  appropriate. 
Pioneering  in  biotechnology  has  to embrace  both  the  specific  requirements 
of  sectoral policies (agriculture and  food,  pharmaceuticals,  chemicals, 
environment,  ••• )  and  the  more  general,  horizontal  (i.e.non-sector-spe-
cific)  needs  for  strategic  applied  research.  In  this  context,  the 
current  modest  Biomolecular  Engineering Programme  should  be  seen  as  only 
a  beginning.  The  number  and  quality of  proposals  submitted  in  1982  have 
demonstrated  the  interest  and  capability of  the  European  research  cen-
tres, and  the  resources  and  terms  of  reference of  B.E.P.  are far  from 
covering  the total  needs.  The  topics  below- not  an  exhaustive list-
illustrate areas  of  strategic need,  and  are  Loosely  grouped  into three 
categories 
1.  removal  of  significant  current  obstacles  to biotechnological  deve-
Lopment; 
2.  methodological  advances  in  fundamental  techniques; 
3.  research  in  support  of  long-term  strategic goals. 
1.  Removal  of  significant  current  obstacles  to biotechnological 
development. 
~i£!2~i2!_QD1Ei2!29~ (recommended  by  FAST  and  by  the  OECD  study). 
The  maintenance  of  the  performance  and  stability of  microorganisms  (wild 
or  cultivated,  manipulated  or not)  in  fermentation  conditions, particularly 
in  Long-term  continuous  culture,  is  a  significant  problem  in  industrial 
biotechnology.  Unpredictable problems,  unforeseeable  from  bench-scale tests 
reflect  basic  lack  of  understanding  of  some  aspects  of  microbial  metabolism 
and  physiology. 
, - 83  -
the other  side of  the  But  this  is only  the  negative  aspect  of  the  subject 
coin  is the  enormous,  and  as  yet  Largely  unexplored, potential for  optimi-
sing  the  behaviour  and  performance  of  microorganisms,  through  manipulation 
of  the nutrient  and  environmental  conditions,  with  respect  to  any  chosen 
objective.  For  example, pursuing  Lipids  as  a  goal, Ratledge  has  persuaded 
organisms  to  reach  85%  Lipids  (dry  weight  basis);  !Cl  pursuing  polyhydroxy-
butyrates  have  obtained  80%  (dwb  )  of  this,  in  a  2-stage  continuous process. 
These  are  illustrative examples,  but  a.great  deal  of  scientific work  remains 
to  be  done,  to  underpin  the general  goal  of  using  fermentation  to  add  value 
to  simple  or  readily  available  materials. 
such  a  project  could  offer  ~idespread benefit  and  stimulus  to European 
industrial  biotechnology  a  preliminary  reconnaissance  study  should  be 
commissioned. 
Q2~D§!!~~~-2!9E~§§iD9·  A wide  range  of  technologies  may  be  relevant 
to the  separation, purification  and  other  processes  which  follow  the 
fermentation  step;  and  the  costs  of  these  downstream  processes  are  a 
critical obstacle to the  extension of  biotechnology  from  high  value 
Low  volume  products  to  Larger  scale possibilities (see  reports prepa-
red  by  UMIST  for  FAST).  Each  industrialist  works  out  an  ad  hoc, 
inadequate  solution for  his  own  problem;  fundamental  work  on  filtration, 
~cculation, separation  etc ••  is neglected. 
fr~2Q!~§~I~~!i2D-2!_e12D!_£~112-~DQ_!i§§~~2·  The  storage of  plant 
materials  has  been  relatively  neglected  as  compared  with  that  of 
mammalian  cells  (Looked  after  by  medical  research  interests)  and 
microorganisms  (bacteria, algae,  yeasts,  fungi  - simpler  to store,  and 
supported  by  industrial  interest).  Plant  cell  and  tissue  culture  is 
of  major  Long-term  potential for  propagation  and  for  the  production 
of  complex  naturnl  chemicals,  and  the  Long-term  cold  storage of  the 
materials  is not  well  understood.  The  technology  would  also  be  of 
major  importance  as  a  support  to genetic  conservation  programmes  in 
Europe  and  the  developing  world. - 84  -
As  the "Economist"  expressed  it  (9th October  1982) 
"Chemists  studying  cell  membranes  believe that,  with  a  modest  push  in  the 
right  direction  they  could  Lick  most  of  the outstanding  problems  asso-
ciated  with  preserving  Living  organisms.  The  results  would  provide  an 
enormous  benefit  to  industry. 
Some,  however,  fear  that  it would  also  Lead  to  (possibly  unpatentable) 
Laboratory  techniques  which  would  then  benefit  their  competitors.  Few 
biotechnology  firms  are  therefore  enthusiastic  about  splashing  out  on 
much  research.  This  is precisely the  sort  of  work  that  needs  to attract 
industry  wide  (or  even  international)  support".(our  emphasis). 
2.  Methodological  advances  in  fundamental  techniques 
Of  importance  are  developments  in  sensitive techniques,  increasingly 
"information-intensive"  :  embracing  processes  for  analysis, detection, 
separation,  various  spectrometries,  and  systems  of  molecular  represen-
tation. 
The  use  of  computer  modelling  and  visual  display  of  molecules  of  biolo-
gical  interest  is  rapidly  becoming  one  of  the  most  important  tools for 
both  pure  research  and  the  development  of  pharmaceutical  products  ;  it 
represents  a  move  towards  "computer-aided design"  in  biology.  Many  other 
applications  will  develop  from  it, enlarging  our  understanding  of  mecha-
nisms  and  our  ability to predict- e.g.  the action  of  new  drugs  or  chemi-
cals  on  DNA.  Current  Leadership  in  hardware  and  software  development  is 
with  the U.S.,  through  work  at  NIH  (Maryland),  and  elsewhere  (Stanford, 
San  Francisco,  Washington).  An  immediate  "reconnaissance"  study  should 
Lead  to  an  assessment  of  the  need  for  Community  action. 
This  technique  provides  a  simple graphical  analysis of  the  thousands  of 
proteins  in  a  small  sample  of  cells or  body  fluids  (blood,  urine,  spinal,  •• ) 
When  further  developed,  a  richly  informative  and  non-intrusive diagnostic 
tool  may  result.  Again, u.s.  effort  is  Leading  ;  but  European  centres  of 
activity exist  (Aarhus,  Pasteur,  ••• ). - 85-
Associated  work  should  be  undertaken  on  computerised  data-capture  from 
gel-reading.  Reconnaissance  study  should  Lead  to  an  assessment  of  the 
need  for  Community  action. 
h2~~!_f1g~_Et!g~~!£t  Another  field  in  which  the  interface of  modern  physics 
and  information  technology  (high  frequency  Lasers, various  spectrometries, 
high  speed  computers)  can  interface  with  biological progress  (e.g.  in 
mammalian  cell  culture  and  selective staining)  to produce  bulk  quantities 
of  sorted  cells,  chromosomes  and  DNA  fragments  ;  for  medical  and  genetic 
research,  and  an  unpredictable  range  of  further potential  applications. 
In  vitro culture  and  test  techniques  The  cost,time  and  animal  sacrifice 
involved  in  meeting  current  regulatory  requirements  for  the  development  of 
pharmaceutical,  chemical  and  cosmetic  products  may  be  significantly  reduced 
by  further  progress  in  in  vitro  cell  and  tissue  culture techniques.  Such 
progress  could  be  of  major  significance,  not  restricted to the  industries 
mentioned. 
3.  Research  in  support  of  Long-term  strategic goals 
In  the  Longer  term,  the  chemical  industry  will  have  to  switch  its raw 
material  basis  from  the  convenient  hydrocarbon  chains  of  crude  oil, and 
will  have  to  develop  the  chemistry  of  small  molecules,  e.g.  from  coal 
(via  synthesis gas,  giving  hydrogen  and  carbon oxides)  or  from  methane 
and  methanol  of  renewable  biological origin. 
The  chemo-aUtotrophs  and  methanotrophs  are  micro-organisms  capable  of 
using  these  basic  materials  to  synthesise  complex  and  potentially useful 
molecules,  e.g.  storage polymers  such  as  polyhydroxybutyrate  (a  biological 
plastic).  Fundamental  research  on  these  is necessary  to  underpin  the  Long-
term  future  of  the  European  chemical  industry,  and  to  shorten  the  reaction 
times  when  the  need  for  change  becomes  urgent. - 66  -
B iomo lecular nathologv  .  .  -------------C------ L  The  FAST  programme  has  recommended,  1n  the  L1ght 
of  trends  in  biomedicine  and  advances  in  biotechnology,  that  the  proposed 
programme  in  biomolecular pathology  should  be  revised,  updated  and  re-con-
sidered  (see  Commission  Publication  EUR  6348, "Cellular  and  molecular  biology 
of  the pathological  state  :  a  proposal  for  a  Community  programme  in  biopatho-
Logy",  by  C.  de  Duve,  1979). 
Such  a  programme  would  be  of particular value  in  reinforcing  the much-
needed  bridges  between  molecular  and  cellular biology,  on  the  one  hand, 
and  clinical  medical  research  on  the other. 
6.  4.  In  Conclusion 
It  has  been  emphasised  that  the  above  List  is not  exhaustive.  It cannot 
be  :  for  one  of  the  most  striking characteristics of  the  Life  sciences  in 
current  times  is their dramatic  rate of  progress.  Significant  scientific 
breakthroughs  have  been  occurring  almost  monthly  during  the  preparation of 
this  report.  Long-term  R&D  policy must  therefore  be  robust,  dynamic  and 
flexible. 
It must  therefore  be  the  subject  of  extended  debate,  at  both  expert  and 
popular  Levels,  in  a  process  of  mutual  and  continuing  education.  If the 
present  report  contributes to this process  of  debate  and  Learning,  it will 
have  served  its purpose. 